Effects of Zika virus on neural precursor cell types and microencephaly in a model of direct embryonic murine brain infection by Shelton, Samantha
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2021
Effects of Zika virus on neural
precursor cell types and
microencephaly in a model of




BOSTON UNIVERSITY  
SCHOOL OF MEDICINE 
Dissertation 
EFFECTS OF ZIKA VIRUS ON NEURAL PRECURSOR CELL TYPES 
AND MICROENCEPHALY IN A MODEL OF DIRECT EMBRYONIC 
MURINE BRAIN INFECTION 
by 
SAMANTHA SHELTON 
B.S., B.A., Humboldt State University, 2014
Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
2021 
© 2021 by 
SAMANTHA SHELTON 









First Reader _________________________________________________________ 
 Tarik F. Haydar, Ph.D. 





_ John Connor, Ph.D. 
 Associate Professor of Microbiology 
 
Third Reader _________________________________________________________ 
 Tsuneya Ikezu, Ph.D. 
 Professor of Pharmacology 
iv 
DEDICATION 
I would like to dedicate this work to the animals sacrificed in order to improve our 
understanding of viral infection of the brain. 
v 
ACKNOWLEDGMENTS 
I acknowledge and thank all the people who have believed in me, pushed me, 
trained me, and supported me along this long journey. I could not have come this far 
without the help of friends, family, colleagues, and mentors.
EFFECTS OF ZIKA VIRUS ON NEURAL PRECURSOR CELL TYPES AND 
MICROENCEPHALY IN A MODEL OF DIRECT EMBRYONIC
MURINE BRAIN INFECTION 
SAMANTHA SHELTON 
Boston University School of Medicine, 2021 
Major Professor: Tarik F. Haydar, Ph.D., Professor of Anatomy & Neurobiology 
ABSTRACT 
          Prenatal exposure to Zika virus (ZIKV) can result in microencephaly and congenital 
Zika syndrome but why some brain cells and structures are initially spared by the virus 
is unknown. Here, a novel murine model of ZIKV infection incorporating in 
utero electroporation with cell type specific promotors was used to identify the time 
course of ZIKV infection and to determine which neural precursor cells are initially 
infected or spared. In vivo time course studies revealed early presence of ZIKV in 
apical radial glial cells (aRGCs) while infection of basal intermediate progenitor cells 
climbed after three days of virus exposure. ZIKV-exposed fetal brains exhibited 
microencephaly as early as 1 day post injection, caused by apoptosis and reduced 
proliferation, and this change in brain size persisted until birth regardless of 
developmental age at infection. During infection, 60% of aRGC basal fibers were 
perturbed while 40% retained normal morphology, indicating that aRGCs are not 
uniformly vulnerable to ZIKV infection. To evaluate this heterogeneous vulnerability, 
we generated cell type-specific fate mapping plasmid probes using a previously 
published    single    cell    RNA-Seq    dataset    on    the    E15.5    mouse     neocortical  
vi
vii 
wall. The results indicate that one class of aRGC preferentially expresses the putative 
ZIKV entry receptor AXL, and that these cells are more vulnerable to ZIKV infection than 
the other aRGC subtypes with low AXL expression. Together, these data highlight 
important temporal and cellular details of ZIKV fetal brain infection and may be important 
for prevention strategies and for management of congenital Zika syndrome. 
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INTRODUCTION 
Introduction to Zika virus 
ZIKV was first discovered in the Zika forest of Uganda in 1947 in an infected 
rhesus macaque (Dick et al., 1952). It is an arbovirus in the family Flaviviridae with a 
similar structure to other known flaviviruses such as West Nile, Yellow fever, and dengue 
virus. It was first thought that ZIKV infection was only in monkeys, the species it was 
discovered in. A small proportion of monkeys that tested positive for ZIKV infection 
developed a fever. Neurotropism was discovered in mice as well (Dick et al., 1952). 
However, no human cases of ZIKV infection were reported until the 1960’s when a 
scientist accidentally infected himself while isolating Zika virus from A africanus 
mosquitoes in Uganda (Simpson et al., 1964). However, it is likely that many more cases 
occurred prior that were misidentified as other flaviviruses or were completely 
asymptomatic. The remaining cases of ZIKV infection before 2007 were identified in 
hospital patients with fever, based on serological investigation, although no confirmatory 
viral isolation was done (Olsen et al., 1981). 
Zika has a similar structure to other flaviviruses. The positive sense single stranded 
RNA (10.8kb) genome includes a 5’ untranslated region (UTR), an open reading frame 
(ORF), and a 3’UTR. The ORF encodes one polyprotein that is subsequently cleaved into 
two structural and 7 non-structural proteins (Kuno et al., 2007). ZIKV genome organization 
and replication is similar to other flaviviruses with 7 main steps to replicate; 1) entry, 2) 





fusion and uncoating, 3) translation 4) RNA replication, 5) assembly, 6) maturation, and 
7) release. The precursor membrane, capsid, envelope, and non-structural proteins play 
different roles in host cell binding, RNA replication, and virion assembly (Chambers et. 
al., 1990, Kuno et al., 2007). Proteolytic cleavage of the polyprotein is performed by the 
viral NS2/NS3 protease, host signal peptidase (C/prM, prM/E, E/NS1, 2K/NS4B) and a 
host protease (NS1/NS2A). Viral NS1-5 are responsible for viral replication in the host 
cell. These non-structural proteins together with the viral RNA-dependent RNA-
polymerase, serve as self-cleaving peptidases. The prM protein is then cleaved in the trans-
Golgi apparatus by furin to generate mature virions. The viral E protein makes up the 
majority of the surface of the virion and interacts with host cells to cause infection 
(Chambers et. al., 1990, Faye et. al., 2014). 
 Since the initial discovery of ZIKV in Uganda, it was shown to be present in several 
other countries in Africa including Nigeria (Fagbami et al., 1979), Sierra Leone (Robin et 
al., 1975), Gabon (Jan et al., 1978), Côte d’Ivoire (Akoua-Koffi et al., 2001) and the Central 
African Republic in the 1970’s (Saluzzo et al., 1981). This spurred serological surveys 
outside Africa that found presence of ZIKV India (Smithburn et al., 1954), Pakistan 
(Darwish et al., 1983), Malaysia (Smithburn et al., 1954), Thailand and north Vietnam 
(Pond et al., 1963), Philippines (Hammon et al., 1958), and Indonesia (Olsen et al., 1983). 
Serosurveys in the 1950s, 1960s, and 1970s suggest that ZIKV has spread widely across 
Africa and Asia, extensive cross-reactivity between various flavivirus antibodies made 
interpretation difficult. Since the development of more specific neutralization assays, 
widespread circulation of ZIKV has been confirmed in Africa and Asia. Isolation of ZIKV 





from Aedes aegypti mosquitoes in Malaysia in 1966 compared to ZIKV isolation in Aedes 
aegypti confirmed the presence of an Asian and an African lineage of ZIKV (Marchette et 
al., 1969).  
 The MR766 strain of ZIKV isolated in Uganda is considered the classical strain and 
has been used in many studies despite having been passaged 147 times. Comparing the 
African strain to the Asian strain of ZIKV reveals about 50 lineage specific mutations, most 
of which are in the NS proteins (Anfasa et al., 2017, Gong et al., 2017, Metsky et al., 2017, 
Beaver et al., 2018). These NS protein mutations lead to phenotypic differences where the 
Asian lineage shows decreased cell death, increased immune system evasion, decreased 
neural precursor cell (NPC) proliferation. Additionally, these mutations aided human to 
human transmission through sexual transmission, blood transfusion, ocular transmission, 
or vertical transmission from mother to fetus (Beaver et al., 2018, Venturi et al., 2016, 
Mansuy et al., 2016). 
 The most common route of infection is from mosquitos to humans (Haddow et al., 
2012). Aedes africanus and Aedes aegypti were the first ZIKV transmission vectors 
discovered (Dick et al., 1952, Haddow et al., 1964, Weinbren et al., 1958). Additionally, 
Aedes luteocephalus (Fagbami et al., 1979), Aedes vittatus (Akou-Kiffi et al., 2001, Diallo 
et al., 2014), Aedes furcifer (Akou-Kiffi et al., 2001, Diallo et al., 2014), Aedes 
apicoargenteus (Haddow et al., 2012, Weinbren et al., 1958, McCrae et el., 1982), Aedes 
hensilli (Ledermann et al., 2014), and Aedes albopictus (Grard et al., 2014) have all been 
found to transmit ZIKV. Of particular concern is Aedes aegypti due to their large 





population and distribution across the equatorial belt (Campbell et al., 2015, Olsen et al., 
1981, Akoua-Koffi et al., 2001, Marchette et al., 1969, Li et al., 2012). Other routes of 
transmission include blood transfusion, sexual transmission, and maternal-fetal 
transmission via placental passage to the fetus or from breast milk (Venturi et al., 2016, 
Mansuy et al., 2016, Musso et al., 2015, Gourinat et al., 2015, Korhonen et al., 2016, 
Shinohara et al., 2016, Fonseca et al., 2014).  
 Symptoms in adults include fever, rash, headache, joint pain, conjunctivitis, and 
muscle pain (Musso et al., 1954, Duffy et al., 2009). Symptoms typically last between 4 
days to a week and can be confused with the common cold. In fact, over 60% of ZIKV 
infections are asymptomatic. Despite there being no reports of ZIKV infection in humans 
until the 1960’s, between the high rate of asymptomatic cases and the similarity of 
symptoms with other flaviviruses that are endemic in the same areas as ZIKV, it is likely 
that many cases were not diagnosed or were mis-diagnosed. Prior to 2007, ZIKV infection 
in adults were considered mild. However, the 2007 ZIKV outbreak in the Yap islands 
revealed 49 individuals reported as having clinical symptoms. In 2013 the ZIKV outbreak 
in French Polynesia revealed the first ZIKV associated birth defects and Guillain-Barré 
syndrome (GBS) (Musso et al., 1954, Cao-Lormeau et al., 2016, Oehler et al., 2014). GBS 
is a rare disorder in which the immune system begins to attack nerve cells after a viral 
infection. This causes weakness in the limbs and in severe cases can affect the muscles that 
control breathing. While the majority of patients recover from GBS after a few months, 
some cases are lethal. It is now known that ZIKV has a strong correlation with GBS. 
Although GBS had been associated with other flaviviruses, the 20-fold increase in GBS 





observed during the ZIKV epidemic in French Polynesia was surprising (Musso et al., 
1954, Cao-Lormeau et al., 2016, Oehler et al., 2014). Given the typically low incidence of 
GBS, correlation to a specific virus can be difficult, especially in endemic regions (Besnard 
et al., 2016). It was not until a retrospective case-control study that the association between 
ZIKV infection and GBS was discovered (Cao-Larmeau et al., 2014, Bautista et al., 2016, 
Fontanet et al., 2016), and the association was subsequently confirmed in the Americas 
(Dos Santos et al., 2016). Additionally, during the 2015 ZIKV epidemic in Brazil, a 20-
fold increase in the incidence of microcephaly coincided with reports of rash, compatible 
with ZIKV fever in pregnant women (Kleber et al., 2016). The link between ZIKV 
exposure during pregnancy and children born with severe central nervous system 
malformations was later confirmed to be microcephaly and congenital Zika syndrome 
(CZS) (Driggers et al., 2016, Mlakar et al., 2016, Brasil et al., 2016, Rasmussen et al., 
2016).  
 Microcephaly is defined as a head circumference more than 2 standard deviations 
(SD) smaller than the average for the child’s age, sex, and ethnicity (CDC, 2016). It was 
suspected that ZIKV was associated with microcephaly 2007 outbreak in Yap but it wasn’t 
until after the 2015 outbreaks in Brazil that the microcephaly phenotype was confirmed. 
Retrospective studies of cases in Yap were then able to confirm microcephaly was a result 
of Zika infection during pregnancy (Musso et al., 1954, Duffy et al., 2009, Baud et al., 
2017). Additional neurological issues started to become apparent in infants who were 
exposed to ZIKV. Other symptoms include brain calcifications, ventriculomegaly, 
hypoplasia, and in severe microcephaly (more than 3 SD below the mean), fetal brain 





disruption sequence (FBDS) was present (Driggers et al., 2016, Mlakar et al., 2016, Brasil 
et al., 2016, Rasmussen et al., 2016, Corona-Rivera et al., 2001). Russell et al., (1984) 
defined FBDS by severe microcephaly, overlapping cranial sutures, prominent occipital 
bone, and redundant scalp skin, in addition to severe neurologic impairment. There is often 
extreme craniofacial disproportion with depression of the frontal bones and parietal bones, 
which can overlap. Typically, affected fetuses are noted to have decreased head 
circumferences in utero (Sarno et al., 2016). To describe the spectrum of phenotypes 
caused by ZIKV exposure in utero, the term congenital Zika syndrome (CZS) was coined. 
Effects of CZS include impairments in cognition, developmental milestones, hearing, 
vision, swallowing and the onset of seizures (Driggers et al., 2016, Mlakar et al., 2016, 
Brasil et al., 2016, Rasmussen et al., 2016).  
 Longitudinal studies of developmental outcomes for infants with CZS are needed. 
FBDS provides a framework for what to expect from the neurological impairments caused 
by CZS. Research on infants with FBDS has shown that severe neurological impairments 
are most common. Many infants do not survive and of those that do, developmental 
milestones past 2 months of age are rarely surpassed. (Corona-Rivera et al., 2001). Infants 
born after the 2013-2014 ZIKV outbreak in French Polynesia and presumed to have been 
infected in utero had severe neurological impairments such as motor and cognitive 
disabilities, seizures, and swallowing difficulties, leading to failure to thrive. Severe vision 
loss and hearing impairments were also present (Besnard et al., 2016). In a series of 
newborns with CZS, 12.5% had severe microcephaly (Martines et al., 2016) and 
sensorineural hearing loss was documented in 5.8% of infants with ZIKV induced 





microcephaly (Leal et al., 2016). Neurological examination of infants with CZS revealed 
hypertonia, spasticity, and irritability (Schuler-Faccini et al., 2015, Silva et al., 2016). In 
addition, children born with CZS are at increased risk of tremors and seizures (Schuler-
Faccini et al., 2015, Culjat et al., 2016, Silva et al., 2016). While there is no treatment for 
microcephaly or CZS, early childhood intervention programs that include speech, physical 
and occupational therapy are the best option for improving symptoms. Effects from 
microcephaly such as seizures or hyperactivity can be mitigated pharmacologically 
(Bernatchez et al., 2020). 
Treatments 
 There are currently no available treatments or vaccines for ZIKV infection despite 
the large effort from the scientific community since 2015. Out of 45 proposed vaccine 
candidates only 2 have advanced to phase 2 clinical trial. The first vaccine candidate is 
mRNA-1325 sponsored by Moderna Therapeutics (NCT03014089) and the second is 
VRC-ZKAD- NA085-00-VP sponsored by NIH-NIAID (NCT03110770). The former trial 
utilized an mRNA delivery system targeting ZIKV prM as immunogen; this trial was put 
on hold to create the COVID-19 vaccine that models it. The DNA delivery system utilized 
in the latter trial targets the ZIKV prM. There are multiple reports of successful safety data 
and immunogenicity of the vaccine candidates (Tebas et al., 2017, Modjarrad et al., 2018, 
Gaudinski et al., 2018). A major challenge in ZIKV vaccine development is the difficulty 
in recruiting subjects for the trials. The decrease in recent ZIKV infections and the variable 
expression of symptoms and severity complicate single end point definitions and 





jeopardize the current and future clinical studies with ZIKV (Wilder-Smith et al., 2018). 
There are however, a number of pharmaceutical interventions under investigation to inhibit 
ZIKV infection. 
 There are 6 main mechanisms of action for antiviral agents that target ZIKV. These 
include entry blockers, RNA-dependent RNA polymerase inhibitors, protease inhibitors, 
assembly inhibitors, endosomal fusion/autophagy, and nucleoside biosynthesis inhibitors. 
There are drugs under development or under investigation for re-purposing in each of these 
6 categories, providing hope that a treatment for ZIKV infection will be available soon. A 
relevant example is the inhibition of viral entry receptors. This is an attractive method to 
avoid ZIKV entry into a host cell. Controversy over the exact host receptor responsible for 
ZIKV entry leaves an unclear target for inhibition. It has been found that the ZIKV E 
protein binds to the ligand Gas6 which initiates clathrin mediated endocytosis via the AXL 
receptor. AXL is a TAM receptor (Tyro3, AXL, and Mertk) that regulates immune response 
in a cell type specific manner. Knock out studies have shown that host cells are vulnerable 
to infection without the presence of AXL (Wells et al., 2016). Conversely, Strange et al., 
(2019) reported that neutralization of the AXL receptor and its ligand Gas6 strongly 
attenuated ZIKV infection. ZIKV replication may have been attenuated by decreased 
protein levels of suppressor of cytokine signaling 1 and 3 and increased expression of 
interferon-stimulated genes (Strange et al., 2019). Part of the discrepancy in results may be 
due to the use of different techniques and different models in each study. Further analysis 





of the role of AXL and other viral entry candidates are required to determine an appropriate 
target for pharmacological intervention.  
 By screening over 1,000 FDA approved drugs and 1,000 bioactives, it was found 
that nanchangmycin, a natural product produced by Streptomyces nanchangensis, has been 
shown to inhibit viral entry by interfering with binding of AXL receptors and clathrin 
mediated endocytosis (IC50=0.1, CC50=7.0) (Rausch et al., 2017). Decisions on the 
suitability of new treatments are mainly based on the three basic parameters CC50 (as a 
measure of toxicity), IC50 (as a measure of inhibitory potential), and the therapeutic index 
that they yield (TI = CC50/IC50). Given this knowledge, the low IC50 score and high 
CC50 score of nanchangmycin indicate low toxicity and high inhibitory potential, making 
for an exciting drug treatment in terms of safety and potential efficacy. Additionally,  recent 
work has identified synthetic carbohydrate receptors that interfere with the early stages of 
ZIKV infection in Vero and HeLa cells; it is postulated that these compounds act by 
inhibiting the interaction between the virus and cell surface glycans. Given the limited 
biological understanding of ZIKV entry, more target validation research and insight into 
the mechanism of action of these compounds would need to occur. In addition, animal 
studies for these leads must be performed. Nevertheless, these molecules represent a 
starting point for future understanding of the details of ZIKV binding and entry into their 
target cells. 





 While there is much work being done in each of these potential treatment avenues, 
no drugs have been FDA approved for the treatment of ZIKV infection thus far. Any drug 
candidate will need to have a high level of safety and efficacy to protect against human-to-
human transmission via sexual transmission or materno-fetal transmission. It will also be 
important to develop drugs indicated for pregnant women with high placental penetrance 
in order to access the placental epithelium and the neural progenitor cells of the developing 
fetus in order to prevent microcephaly. Drugs need to be designed to cross the blood-brain 
barrier and have a high level of safety in order to treat pregnant women with ZIKV 
infection. 
 A vaccine against ZIKV would be more amenable to prevention of neurological 
malformations in utero. Vaccines against other flaviviruses such as yellow fever and 
dengue provide hope but have many contraindications, including pregnancy (Arredondo-
García et al., 2018, Katzelnick et al., 2017). The dengue vaccine was even confirmed to 
increase risk of cytoplasmic leakage syndrome in patients who had previously been 
exposed to dengue (Aguiar et al., 2017). As many of these flaviviruses are present in the 
same affected areas, this is an important issue to keep in mind in developing a ZIKV 
vaccine. (Aguiar et al., 2017, Halstead et al., 2017, Halstead et al., 2018, Elong et al., 2019). 
To avoid cross-reactivity, the vaccine candidate would ideally be a pan-flavivirus vaccine 
with a single dose regimen. 





Conclusions from therapeutic exploration 
 While ZIKV infections have been decreasing with increased awareness and 
preparedness since the 2015 Brazil outbreak, the threat of a resurgence is always present. 
Without effective antivirals or better, a ZIKV vaccine, the same risk of microcephaly and 
CZS is evident for those wishing to conceive. Regions along the equatorial belt that are 
endemic to flaviviruses continue to have outbreaks of not only ZIKV but also dengue and 
yellow fever virus. The development of inhibitors that could broadly treat multiple 
flavivirus infections would be an ideal strategy in terms of efficiency, financially, but also 
to reduce the risk of vaccine-mediated exacerbation of the symptoms of dengue fever. 
Further research with appropriate models, ZIKV strain, titer, and controls are necessary to 
understand ZIKV infection, host interactions, and initiation of microcephaly and CZS.  
Models of infection 
 Many models have been used to study ZIKV infection, ZIKV induced 
microcephaly, and potential treatments. Cell culture, organoids, slice culture, and a variety 
of animals models have all contributed to our knowledge in various ways. Here we will 
discuss the benefits and limitations of each to better understand the rationale for the model 
presented in this dissertation. 
Cell culture 
 Early cell culture experiments were successful in discovering increased cell death 
and decreased proliferation after infection compared to controls (Tang et al., 2016, Smith 





et al., 2018, Liang et al., 2016). These phenotypes have been corroborated in other models 
and have contributed to our understanding of ZIKV induced microcephaly. Unfortunately, 
cell culture experiments lack cell type diversity, so conclusions about cell type 
vulnerability or cytoarchitecture cannot be made with this model. Cell culture does of 
course make an excellent model for drug compound screening and has been very successful 
in finding compounds that reduce ZIKV infection (Rausch et al., 2017). 
Organoids 
 Organoids build upon the benefits of cell culture in that they have better but not 
complete cell type heterogeneity as well as cytoarchitecture. They do add to our 
understanding of ZIKV induced microcephaly if used correctly. For instance, in Wells et 
al., (2016) cerebral organoids were generated from AXL-WT and AXL-KO-Tm iPSCs to 
assess the role of the candidate entry receptor AXL. They were able to use their organoid 
system to assess cell death, cytoarchitectural perturbation, and microcephaly. However, 
measuring microcephaly in organoids is problematic due to their variable growth, as seen 
by the variability of their data. Additionally, conditioned media from Vero cells was used 
for mock controls while virus was diluted with 1x EBSS. Conditioned media contains 
growth factors released by cells in culture and may result in decreased growth in organoids 
treated with virus compared to controls. A more appropriate comparison would have been 
conditioned media with and without virus. These among other experimental issues in this 
paper make strong conclusions difficult but demonstrate how organoids can model the 
effects of ZIKV infection if done correctly. 






Slice culture is an interesting model that allows for rodent brains to be removed, 
sliced into sections, and manipulated ex vivo. Rosenfeld and colleagues investigated 
multiple strains of ZIKV in slice culture to determine if neurotropism is a recently acquired 
property. To identify differences between isolates from different regions including Puerto 
Rico, Malaysia, African (MR766), Senegalese, Brazilian, Colombian, and Honduran, slice 
cultures were infected with 105 PFU. Plaque assays of each isolate with multiple time 
points were collected for analysis of viral replication. Prominent infection was found in the 
cultures by 8 DPI. Immunofluorescence (IF) analysis was used to detect cleaved caspase 3 
as a marker of apoptosis in the infected brain slice cultures (Rosenfeld et al., 2017). Cell 
death was increased in each isolate compared to controls. Interestingly, the Puerto Rican 
strain did not infect E19 brain slice cultures. Neurogenesis would have just ended 2 days 
prior to this timepoint so the pool of proliferative and highly susceptible cells would have 
completed their divisions, giving rise to immature neurons which are known to be less 
susceptible to infection. MR677 and Honduran strains were able to infect the E19 brain 
slice cultures, showing higher virulence from African lineages compared to contemporary 
strains of ZIKV. 
To determine if ZIKV replication alters neuronal migration in the slice culture, 
GFP-encoding DNA was injected into the lateral ventricle and electroporated ex utero at 
E15. Organotypic cultures were then generated and infected with ZIKV 24 hrs later. The 
authors used this technique to label aRGCs but keep in mind that no cell type specific 
promoter was used. Thus, it cannot be assumed that all of the cells positive for GFP are 





aRGCs. The percentage of GFP positive cells in the outer layers of the slice were 
significantly decreased after infection, indicative of halted neuronal migration.  
Together, Rosenfeld and colleagues showed data that support the hypothesis that 
ZIKV infection can cause structural changes to the basal process of the radial glial 
progenitor cells in their slice cultures and that decreased GFP in the outer layers was 
indicative of impaired neuronal migration. Analysis was done at 4DPI, leaving the 
developmental stage of the tissue at E20. There is no rational for a 4DPI time point here 
and results in fixation and staining at a post neurogenesis time point that falls somewhere 
between embryonic and post-natal development. During that 5-day course electroporated 
aRGCs would have divided to make all other neural precursor cell types, neurons, and glia. 
These other cells also have extended fibers that span the cortical plate. By using GFP 
electroporation without aRGC specificity, the conclusions about aRGC fiber perturbation 
and neuronal migration cannot be made. At minimum, IF for aRGC and neuronal markers 
would have to be used in conjunction with IUE to label cells, making percent GFP by bin 
a poor analysis that lacks normalization to the electroporated area. 
This article serves as an example of the strong potential for slice culture models to 
inform ZIKV neurotropism. However, some of the inherent challenges of slice culture 
include the innate immune response caused by removing the brain from the skull, the need 
to keep the cells alive in artificial cerebral spinal fluid after sheering the cell membranes 
with a vibratome, increased cell death and the release of internal factors into the 
environment, inability to study microcephaly, and the vague time points that fall between 
pre and post-natal development. Repeating experiments from Rosenfeld et al. (2016) in 





vivo, with thoughtful controls, and quantification will add to our understanding of ZIKV 
infection.  
Animal models of ZIKV infection 
 A number of animal models have been utilized to study ZIKV infection. In mice, 
pregnant dams have been infected with ZIKV using intraperitoneal injection or intrauterine 
injections to study virulence and vertical transmission from the dam to the pups. These 
studies elucidated the microencephaly phenotype in murine models and shed light on the 
role of microglia in vertical transmission using the PRVABC59 2015 Puerto Rico strain 
(Wu et al., 2016, Xu et al., 2020). Unlike humans, mice do not become 
immunocompromised during pregnancy, making the mouse a difficult model to induce a 
realistic infection in developing pups. 
 To better model embryonic infection, Li et al. (2016) infected interferon-knockout 
dams with 105 PFU of the Asian strain SZ01 of ZIKV. This leads to evidence of neural 
stem cell infection in the SVZ and subgranular zone of the hippocampal dentate gyrus. 
However, interferon regulates cellular proliferation and differentiation, making knockout 
of interferon a poor model to study ZIKV progression in vivo (Clemens et al., 1985). 
 To model embryonic infection in vivo in an immunocompetent, scientists have 
injected 105 PFU of the Asian strain SZ01 of ZIKV directly into the lateral ventricle of 
developing mice in utero (Cui Li et al, 2016, Li et al., 2016, Qiang Shoa et al., 2017). This 
is an excellent model to study ZIKV infection in vivo. Researchers have even added in 
utero electroporation with green florescent protein driven by a CAG promotor (CAG-GFP) 





to be able to label cells in the VZ during infection. The major limitation here is the lack of 
cell type specificity in using a CAG-GFP. Additionally, there was no discussion of how 
IUE might change the progression of ZIKV infection (Li et al., 2016). Alternatively, 
researchers have electroporated embryonic murine brains with specific ZIKV proteins 
tagged with GFP to determine if the envelope or structural proteins cause microcephaly 
(Yoon et al., 2017, Bhagat et al., 2018). The pitfall of this technique is that the study of 
viral replication is hindered by the lack of active ZIKV. Not only is the natural progression 
of infection missing, but the reporter tends to dilute to non-detectible levels after 24-48hrs. 
 Animal models other than mouse models have also contributed to the field. For 
instance, in a study on pregnant pigtail macaques, ZIKV-induced injury to fetal brain was 
shown to be substantial even in animals that did not have microcephaly (Adams Waldorf 
et al., 2016). This finding has important implications for the monitoring and treatment of 
children exposed to ZIKV in the womb who were not born with microcephaly. 
Additionally, ZIKV infection of nonhuman primates infected with Asian/American ZIKV 
strain in early gestation experienced fetal demise later in pregnancy despite showing few 
clinical signs of infection (Dudley et al., 2018). ZIKV infection may therefore be causing 
more miscarriages than currently recognized. These experiments made major contributions 
to clinical monitoring as non-human primates have such closely related brain development 
to humans. The pitfall of this model type is of course, the ethical dilemma of infecting 
pregnant sentient animals. 





Neurogenesis and neural precursor cell heterogeneity 
 Successful brain development relies on a carefully curated combination of founder 
cell expansion, NPC proliferation, cell cycle duration, cell death, differentiation, and 
migration. Insult to any one aspect, regardless of genetic or environmental etiology, can 
drastically interfere with brain development. The ways in which ZIKV interfere with these 
essential mechanisms needs to be explored in order to understand the root cause of 
microcephaly. 
 While ZIKV-induced microencephaly is devastating and even lethal, the infection 
route and cellular mechanisms contributing to ZIKV-induced microencephaly are not 
completely understood. ZIKV infection during pre-natal development can impact NPC 
survival, proliferation, and function but the viral entry receptor and NPC type are still 
debated. NPCs will eventually give rise to all neurons in the brain. Thus, the way in which 
NPC populations are altered by ZIKV exposure could result in fewer types of specific 
neurons being born to populate the cortex, resulting in microencephaly and mal-developed 
neural circuits. 
 NPCs are a diverse population of cells that can be categorized into sub-classes that 
are distinct from one another in terms of types of cells they give rise to, unique 
transcriptional profiles, morphology, and location within the VZ and SVZ (Malatesta et al., 
2000, Miyata et al., 2001, Noctor et al., 2001, Rakic et al., 2009, Kriegstein et al., 2009, 
Tyler et al., 2015, Li et al., 2020). It is possible that these differential characteristics make 
certain classes of NPCs more vulnerable to ZIKV infection than others. Previous studies 





have shown that aRGCs are preferentially targeted by ZIKV while others have suggested 
that basal intermediate progenitor cells (bIPCs) are the target of infection (Onorati et al., 
2016, Lin et al., 2017). However, the majority of ZIKV studies have overlooked the 
differences between these classes of progenitor cells and have conducted analyses as if all 
NPCs were one cell type, potentially overlooking the more nuanced mechanisms of ZIKV 
infection and consequent changes in neuronal output.  
 As each class of NPC uniquely contributes to the developing brain, it is important 
to study the effects of ZIKV on each type of NPC individually and the consequences of 
infection on neurogenesis and cortical expansion. Neurogenesis occurs in mice between 
embryonic day (E)11-18.5. Generation of neurons is either through a direct or indirect 
stream. Direct neurogenesis involves the differentiation of neural epithelial cells (NEPs) to 
aRGCs that then divide to create neurons. Indirect neurogenesis is the process of 
differentiation from NEPs to aRGCs that give rise to basal radial glia (bRGCs), bIPCs, and 
short neural precursors (SNPs) or apical intermediate progenitor cells (aIPCs) that give rise 
to neurons (Rakic et al., 1988, Rakic et al., 1988, Rakic et al., 1995, Tyler et al., 2013). 
This period of cortical expansion is essential to brain development as the ratio of direct and 
indirect neurogenesis has a large impact on the eventual size and neuronal complexity of 
the neocortex (Rakic et al., 1988, Rakic et al., 1988, Rakic et al., 1995). Without controlled 
proliferation, cell survival, cell death, migration, and appropriate cell fate, the brain is at 
risk of malformation. Thus, if ZIKV targets a particular class of progenitor cells for 
infection and at a specific point during neurogenesis, this could drastically change neuronal 
output, leading to abnormal brain development and microencephaly. This area of NPC 





heterogeneity is integral to understanding corticogenesis. The cerebral cortex is the root of 
cognition and the human experience. The advanced networks in the cerebral cortex 
construct higher intelligence and lend to our perception of reality. Recent research has 
begun to unveil even more complexity of NPC populations and their divergence in the 
creation of functionally distinct neurons in the cerebral cortex. Further research in NPC 
heterogeneity is required to understand the complexity of neural diversity and the 
functional role of cortical circuits. This will not only elucidate cell type specific 
vulnerability to ZIKV but also inform corticogenesis. 
 In addition to identifying the selective infectivity of the various NPC classes as a 
mechanism of ZIKV-induced microencephaly, further investigation into virus-host 
interactions is necessary to understand ZIKV entry into certain cell classes. Many viral 
entry receptors have been explored as candidates mediating ZIKV infection including 
Tim1, Tyro2, MERK, and AXL (Bhattacharyya et al., 2013). There has been much debate 
in the field as to which of these are required for ZIKV infection in the brain. The lack of 
thorough in vivo studies with appropriate models have hindered our understanding of NPC 
susceptibility and the entry mechanism in ZIKV infections. One factor contributing to the 
discrepancies in published findings is the varied methodology and model systems used for 
ZIKV infection. Initial ZIKV studies utilized multiple models such as cell culture, 
organoids, slice culture, and animal models to understand the mechanisms behind ZIKV-
induced microencephaly. However, these studies have had many obstacles to overcome. 
For instance, the human immune system is compromised during pregnancy and leads to 
increased risk of embryonic viral infection. This is not the case for mice, where the 





maternal immune system is fully competent, making the study of ZIKV in a murine model 
difficult. To circumvent this, interferon knock-out mice have been used to study ZIKV 
infection in mice (Bhattacharyya et al., 2013). However, the loss of interferon in the brain 
likely alters the natural progression of infection, cell death, and proliferation, making 
strong conclusions difficult (Bhattacharyya et al., 2013). Alternatively, studies have 
utilized organoids or stem cell cultures, which do not represent the full complexity of brain 
development (Tang et al., 2016, Miner et al., 2016). Some studies have used in utero 
electroporation (IUE) but lacked cell type specific promoters to test specific populations of 
NPCs rather than non-selectively labeling all of the electroporated cells with GFP 
(Rosenfeld et al., 2017, Yoon et al., 2017). Additionally, studies were done with inactivated 
ZIKV or one of the first available strains of the virus, MR-766 (Gadea et al., 2016, Tang 
et al., 2016). Unfortunately, conclusions drawn from these studies have been criticized due 
to lack of viral transmission and the high passage number of MR-766 respectively. It is 
important to study active ZIKV infection in an appropriate model in order to understand 
why some cell types and brain regions are spared from ZIKV while others are vulnerable 
to infections and altered during development. Understanding these mechanisms will be 
helpful in developing treatment for patients born with ZIKV induced microencephaly and 
will also inform the mechanism of action that newly evolving viruses use to infect the brain. 
 To overcome these previous challenges, we developed a method to infect, in vivo, 
a non-immunocompromised mouse model with a contemporary strain of active ZIKV with 
low passage number and physiological titer of virus to determine the impact of ZIKV on 
brain development across time and developmental stage (Fig. 1). To study infection of 





NPCs in the developing brain without altering innate immune response, we adapted IUE, 
a technique that uses short pulses of electricity to open the cell membrane and allow 
plasmid DNA to enter. Cell type specific promoters were used in combination with a cre-
recombinase dependent dual reporter to label cells of interest in red (mCherry) and total 
electroporated cells with green fluorescent protein (ZsGreen). This technique leveraged the 
unique transcriptional profiles of each NPC group to study ZIKV infection across time in 
vivo. 
 In this work, we have developed and validated a novel way to infect non-
immunocompromised mice with ZIKV to track the effects of viral exposure on fetal brain 
development and identify the underlying mechanisms of ZIKV-induced microencephaly. 
This model has shown that embryonic exposure to ZIKV results in microencephaly in mice 
after just one day and persisted consistently regardless of age at infection. Using cell type 
specific promotors and time point studies we found that aRGCs are most vulnerable from 
1-3 days post infection (DPI), and that bIPCs were more vulnerable at 3DPI. Thereafter 
infected cell numbers decreased equally in both cell types. Cell death increased and 
proliferation decreased, likely contributing to the microencephaly phenotype. IUE revealed 
that 60% of aRGC basal fibers were disrupted which also likely contributes to 
microencephaly as basal fibers are required for neural migration and maturation. The 
population of aRGCs with undisturbed basal processes present the possibility of subtypes 
of aRGCs with differential vulnerability to ZIKV infection. Using published scRNAseq 
data, we identified markers specific to two separate groups of aRGCs and developed tools 
to test the hypothesis that these two subtypes of aRGCs exist in vivo as distinct cell types. 





The two groups of aRGCs were found in vivo and showed differential vulnerability to 
ZIKV. Additionally, the more vulnerable group of aRGCs was found to contribute 
preferentially to direct neurogenesis while the protected group of aRGCs contributed 
preferentially to indirect neurogenesis. Our findings presented here demonstrate the 
effective use of a novel in vivo method for studying the effects of ZIKV infection on the 
developing brain and provide new insight into corticogenesis and potential downstream 
effects on neural circuits in adults born with microencephaly.  








Figure 1. Intraventricular ZIKV model and genetic fate mapping 
approach. A) Embryos injected with 10,000 FFU ZIKV or saline, Tbr2-Cre, 
and stop light reporters driven by a CAG promoter are injected into the 
lateral ventricle. B) The electroporation results in ZsGreen electroporated 
NPCs and mCherry bIPCs. C) IUE experiments include collection on E13.5-
18.5 encompassing early, mid, and late neurogenesis. The collection scheme 
for E12.5 viral infections is outlined by blue arrows as an example for all 
other infection timepoints. 





MATERIALS & METHODS 
ZIKV production 
 Vero E6 cells were maintained and passaged in cMEM (MEM [Gibco] containing 
10% FBS [Sigma Life Science]). The ZIKV PRVABC59 (2015 Puerto Rico strain, 
GenBank KZ087101.2) was obtained from BEI resources. Master stocks were prepared 
from supernatants of Vero E6 cells infected at low MOI as previously described in 
Rossignol et al., (2017).  
Animals and in utero electroporation (IUE) 
IUE was performed on timed pregnant CD-1 dams purchased from Charles River 
Laboratories. Dams were anesthetized via intraperitoneal injection of a 10 mg/kg mixture 
of ketamine/xylazine. The uterine horns were exposed by midline laparotomy. Two 
microliters of plasmid DNA mixed with 0.1% fast green dye (Sigma-Aldrich) were injected 
through the uterine wall and amniotic sac into the lateral ventricle of the developing mouse 
via a pulled and beveled glass micropipette. Cre and reporter plasmid DNA were mixed at 
a 1:1 ratio by copy number, and the final concentration of each plasmid was between 2 and 
3 μg/μl. The anode of a Tweezertrode (Harvard Apparatus) was placed over the dorsal 
telencephalon above the uterine muscle, and four 35 V pulses (50 ms duration separated 
by a 950 ms interval) were applied with a BTX ECM830 pulse generator (Harvard 
Apparatus). Following electroporation, the uterine horns were returned to the abdomen and 
the cavity was filled with a warm 0.9% sterile saline solution. The incisions were closed 





with silk or absorbable sutures depending on the duration of the experiment. Dams were 
then placed in a clean cage and monitored closely during recovery.  
 To model infection of a contemporary ZIKV in fetal brain, we chose to directly 
inject the Puerto Rican strain (PRVAB59) into the lateral ventricle of prenatal mice in 
utero. The concentration was determined after initial tests of infectability at concentrations 
ranging from 1,000-12,000 focus forming units (FFU). We used the lowest concentration 
able to cause reliable infection to better model the expected viral load that would be 
transmitted by infected mothers to human fetuses. The average bolus from the Aedes 
aegypti mosquito is 104 -108 FFU. Some of that bolus is cleared from the maternal blood 
stream before infecting a fetus, making the expected titer around 101-3 FFU (Dudley et al., 
2017). 103 FFU was sufficient to cause infection in mice without causing large scale cell 
death. Antibodies to ZIKV envelope protein resulted in false positives in western blot, 
therefore antibody against non-structural protein 2b (NS2B) was used for all experiments. 
To infect embryos at the time of IUE, 103 FFU was added to the plasmid DNA and fast 
green dye cocktail in place of saline. Embryos in one uterine horn were injected with 
plasmid DNA cocktail containing virus and embryos in the contralateral uterine horn were 
injected with plasmid DNA cocktail containing saline in order to provide an age-matched 
vehicle control. Immunohistochemistry (IHC) against ZIKV and reverse transcription 
quantitative polymerase chain reaction (RT-qPCR) were conducted to ensure that ZIKV 
did not infect the control embryos. These procedures were reviewed and approved by the 
Institutional Animal Care and Use Committee at the Boston University School of 
Medicine. 






 A 2.9kb fragment of DNA upstream of the Prc1 translation initiation site was 
amplified by PCR from mouse genomic DNA with Phusion high fidelity DNA polymerase 
(New England Biolabs). Restriction enzyme sites (KpnI and XhoI) were added to the sense 
and antisense primers to enable cloning into a Cre expression plasmid in two pieces  
(For: TACCGTTCTCCGTCCCGCTCGAGGGGCAGAGCCG;  
Rev: GCTCTGCCCCTCGAGCGGGACGGAGAACGG;  
For: GGCGAATTGGGTACCCTTGGCTTGCTAGGGTGTGA;  
Rev: CCCTAGCAAGCCAAGCGCTATC).  
The 3.2kb Robo4 promoter was amplified with the same restriction sites using  
For: GGCGAATTGGGTACCCATGCATTTGGAGTTTCCATGTCCT and  
Rev: GCTCTGCCCCTCGAGGGCTGCTCTCGGCTCC.  
The MFAP2 promoter was amplified the same way using primers  
For: GGCGAATTGGGTACCACTCGATCTCCCTTAATCTGCCT;  
Rev: GGCGAATTGGGTACCACTCGATCTCCCTTAATCTGCCT. 
 
Amplified DNA was first purified with a QIAquick PCR purification kit (Qiagen), 
digested with the appropriate restriction enzymes, and gel purified along with the recipient 
Cre expression plasmid using the Qiaquick gel extraction kit. The promoter fragment was 
ligated into the Cre plasmid backbone using the Mighty Mix DNA ligation kit (Takara) 
and transformed into chemically competent DH5a cells (Invitrogen) for selection by 
growth on LB Amp agar plates. Cloning was confirmed by DNA sequencing. 






RNA was extracted from flash frozen tissue with a Qiagen RNeasy kit per 
manufacturer recommendations. Quantitative RT-qPCR was carried out with a Roche one-
step SYBR ZsGreen kit. Primers used were ZIKV For: 
AARTACACATACCARAACAAAGTGGT and ZIKV Rev: 
TCCRCTCCCYCTYTGGTCTTG. 
Lipophilic staining 
1 mg/mL of DiI was dissolved in 100% ethanol and allowed to air dry on a petri 
dish until crystals formed (~1hr). Meninges were removed from brains that were fixed in 
4% PFA overnight. The dorsal surface of the brain was rolled over the bed of DiI crystals 
to create a uniform coating. The labeled brains were stored in 0.02% sodium azide in PBS, 
light protected at room temperature for 2 weeks. Brains were mounted in 4% agarose and 
cut into 80μm sections with a Leica VT1000S vibrating microtome. 75μm Z-stack images 
were taken using an upright Zeiss LSM 710 microscope. Cells were manually scored and 
counted using the LSM image browser software.  
Immunohistochemistry 
Embryos were collected at 1-6 DPI and the heads were fixed overnight in 4% PFA, 
cryoprotected in 30% sucrose for 24–48hr, and frozen in OCT compound in tissue molds 
with an ethanol/dry ice bath. Frozen tissue was cut into 16μm sections using a HM 550 
Cryostar cryostat and mounted and dried onto superfrost slides. 
 





Before staining, frozen sections were air dried for 1hr and washed three times in 
PBS for 5 min each. Sections were then blocked in diluent (5% goat serum, 0.3% Triton 
X-100, 1× PBS) for 1hr at room temperature.  
Incubation with primary antibodies, mouse anti-Ki67 (1:250, Thermofisher), rabbit 
anti- Ph3 (1:300, Millipore), rabbit-Tbr2 (1:500, Millipore), goat anti-Sox2 (1:250, Santa 
Cruz), rabbit-NS2B (1:250, Genetex), and rabbit anti-Cleaved Caspase 3 (1:250, Cell 
Signaling) were performed overnight at room temperature. Following three 5 min washes 
in PBS, sections were incubated for 2hr at room temperature in diluent containing the 
appropriate Alexa-conjugated secondary antibodies (1:500 for all). Sections were washed 
an additional three times for 5 min and stained with Hoechst at 1:1000 in PBS for 10 min. 
Slides were washed with 1X PBS three times for 5 min and cover slipped with 
Flouromount-G. The 20× Z-stack images (20μm) were acquired using an upright Zeiss 
LSM 710 microscope and positive cells from n = 4 brains were identified and counted 
using LSM image browser software.  
 ZsGreen+ and mCherry+ cells from electroporation were manually scored and 
counted using the LSM image browser software. Cells were classified as “ZsGreen+” if 
they expressed ZsGreen but contained no signal for mCherry. Correspondingly, cells were 
classified “mCherry+” if they contained mCherry signal, whether or not they were also 
ZsGreen+ due to perdurance of the fluorescent protein, remaining copies of unrecombined 
reporter plasmid, or due to the presence of a subpopulation of precursors transitioning from 
an apical to a basal fate.  





Fluorescent in situ hybridization 
Fluorescent in situ hybridization was performed using the RNAscope (ACDbio) 
protocol for fixed frozen sections with the modification of using 100% methanol with 3% 
hydrogen peroxide rather than using 100% peroxide to preserve the integrity of the tissue. 
Cells were counted as being positive if they had 2 or more puncta co-localized to the 
nucleus labeled with Hoechst. The 20× Z-stack images (20μm) were acquired using an 
upright Zeiss LSM 710 microscope and positive cells from n = 4 brains were identified and 
counted using LSM image browser software.  
Analysis of differentially expressed genes from scRNAseq data 
 Genes that had high expression in only one group and that were expressed in the 
majority of cells within a group were then assessed for location of gene expression. The 
online Allen Brain Atlas was used to investigate in situ hybridization of genes of interest 
to verify expression in the VZ of developing mouse brain. From there, a short list was 
generated of genes that showed a significant difference in gene expression between aRGC 
group 1 and 2, that had high expression in many cells within their cluster and showed gene 
expression localized to the VZ of the developing murine cortex. Markers who showed 
expression in cell types other than aRGCs and that were expressed outside of the VZ at 
E15.5 were excluded. Additionally, the find markers algorithm in the Seurat package 
offered in R was used to corroborate this list. Only the two most specific markers were 
used for each aRGC group. 






 A Student’s t-test was run for the log fold change of each gene in aRGC group 1 
and 2 to compare differential gene expression between the two groups. Histograms of z-
scores were generated for genes that reached significance. Genes that had high expression 
in only one group and that were expressed in the majority of cells within a group were then 
assessed for location of gene expression. These top candidate markers were secondarily 
validated with the Seurat Find Markers algorithm. 
Cell counts were analyzed in Microsoft excel and Prism using a two-way Student’s 
t-tests with a P-value of < 0.05 considered statistically significant when comparing control 
and infected samples. When comparing statistical differences among the means of two or 







Development of an in vivo mouse model of ZIKV infection 
Introduction  
 The 2015 Brazilian ZIKV outbreak has been associated with an estimated 20-fold 
increase in cases of microcephaly in newborns (WHO, 2018). Despite the strong 
association between prenatal ZIKV exposure, the devastating effects of microcephaly, and 
the initial rapid response by the biomedical community to the threat posed by ZIKV, there 
are no available treatments or approved vaccines for ZIKV (CDC, 2016). Greater 
understanding of the mechanisms underlying ZIKV-induced microcephaly is needed to aid 
in the development of therapeutic strategies. In particular, the infection route and cellular 
mechanisms contributing to ZIKV-induced microcephaly are still unclear. Although 
prenatal ZIKV infection can impact neural cell survival, proliferation, and function, the 
possibility that cells are not uniformly affected by virus exposure may lead to new therapies 
or prevention strategies.  
Various approaches have been used to understand the mechanisms behind ZIKV-
induced microencephaly, such as cell culture, organoids, slice culture, and animal models 
(Miner et al., 2016, Lazear et al., 2016, Bhattacharyya et al., 2013, Tang et al., 2016, 
Nowakowski et al., 2016, Onoroti et al., 2016, Rosenfeld et al., 2017). A major obstacle 
for model development has been the differences in immune response between humans and 
other mammals. While the maternal and fetal immune system is vulnerable to ZIKV 





system and placental barrier prevents fetal infection. To circumvent this, interferon knock-
out mice have been used to study ZIKV infection in the fetal brain (Lazear et al., 2016). 
However, the loss of interferon itself likely alters the natural progression of infection, cell 
death, and proliferation in the central nervous system, impairing the translatability of 
findings from these models (Bhattacharyya et al., 2013, Meertans et al., 2012, Miner et al., 
2016). Studies using organoids or stem cell cultures have demonstrated key aspects of 
ZIKV infection, including increased cell death and decreased proliferation, but these 
methods do not contain the full repertoire of cell types or developmental processes 
necessary for proper brain development (Miner et al., 2016, Lazear et al., 2016, 
Bhattacharyya et al., 2013, Tang et al., 2016, Nowakowski et al., 2016, Onoroti et al., 2016, 
Rosenfeld et al., 2017). Similarly, while studies using in utero electroporation (IUE) have 
identified morphological changes to precursors and neurons in response to ZIKV, they have 
not included cell type-specific labeling strategies (Rosenfeld et al., 2017). Several other 
studies have been performed with inactivated ZIKV or with one of the first available strains 
of the virus, MR-766 (Tang et al., 2016, Gadea et al., 2016). Conclusions from these studies 
have suffered from the lack of viral transmission and the high passage number of research 
stocks of MR-766, respectively. We sought to develop a direct fetal brain infection model 
that circumvents the dam’s immune defenses, permitting study of infection from a 
contemporary strain of ZIKV over the period of cortical development in utero. We have 
combined this direct brain infection model with cell type-specific methods to determine 





 In the mouse neocortex, all lineages of neurons are born between E11 and E17 from 
a diverse population of precursor cell types that generate neurons either directly or 
indirectly from a secondary progenitor. This period of cortical expansion is essential to 
brain development as the ratio of direct and indirect neurogenesis has a large impact on the 
eventual size and neuronal complexity of the neocortex (Rakic et al., 1988, Rakic et al., 
1988, Rakic et al., 1995). Thus, viral effects on individual NPC populations could result in 
smaller populations of their specific neuronal progeny, resulting in microencephaly and 
dysgenesis of particular cell populations in the cortical architecture. Previous studies have 
shown that aRGCs are preferentially targeted by ZIKV while others have suggested that 
bIPCs are the target of infection (Onoroti et al., 2016, Lin et al., 2016). The majority of 
ZIKV studies have not considered the emerging data on differences between progenitor 
cell groups, information that is potentially relevant for understanding the more nuanced 
mechanisms of ZIKV infection and consequent changes in neuronal output. NPCs can be 
categorized into sub-classes by transcriptional profile, morphology, and location within the 
ventricular zone (VZ) and subventricular zone (SVZ) (Fig. 1B) (Tyler et al., 2013, 
Tamamaki et al., 2001, Hartfuss et al., 2001, Gal et al., 2006, Dudley et al., 2017, Rakic et 
al., 1972, Hodge et al., 2019, Englund et al., 2005. Tasic et al., 2018, Heavner et al., 2020, 
Haubensak et al., 2004, Miyata et al., 2004, Noctor et al., 2004, Li et al., 2020). Recent 
advancements in single cell RNA sequencing (scRNAseq) provide the opportunity to study 
the heterogeneity of NPCs and their daughter cells at new levels of resolution. We sought 
to make use of these transcriptomic distinctions between NPCs to determine the cell type-





 We therefore developed a method to directly infect the telencephalon of a non-
immunocompromised mouse with a contemporary strain and physiological titer of active 
ZIKV with low passage number. To study subtypes of NPCs in the infected developing 
brain, we performed IUE during ZIKV exposure (Fig. 1A). Our findings demonstrate the 
effective use of a novel in vivo method for studying the effects of ZIKV infection on the 
developing brain and provide new insight into corticogenesis in children affected by ZIKV 
induced microencephaly.  
 
Results 
Active ZIKV injection into the lateral ventricle of the prenatal mouse brain 
 To model infection of a contemporary ZIKV strain in fetal brain, 10,000 FFU of 
the PRVAB59 strain was injected into the lateral ventricle of prenatal mice in utero. This 
concentration was determined after initial tests of infectability at concentrations ranging 
from 1,000-12,000 FFU. We used the lowest concentration necessary to cause reliable 
infection to better model the expected viral load that would be transmitted by infected 
mothers to human fetuses. The average bolus from the Aedes aegypti mosquito is 101-3 FFU 
(Dudley et al., 2017). We found that 103 FFU was sufficient to cause reliable infection in 
fetal mouse brain. Antibodies to ZIKV envelope protein resulted in false positives in 
western blot, therefore immunostaining for NS2B was used for all experiments. IHC using 
NS2B was used to test for presence of replicating ZIKV in control and infected embryos 





studies were conducted to determine that that virus did not passage between fetuses and 
was not able to cross the cervix to cause infection in the contralateral uterine horn, which 
was used for saline injected controls. Widespread infection was low at one day post-
infection (1DPI) and steadily increased in the following days. By 6DPI, most virus was 
present in the cortical neuron layers and there were no longer any ZIKV positive cells 
remaining in the VZ (Fig. 2).  
Temporal infection of major precursor cell types 
 To distinguish between apical and basal neocortical precursor cells, we used a 
combination of IUE fate mapping, cellular morphology and position within the neocortical 
wall. T- box brain protein 2 (Tbr2) was used as a cell lineage specific promoter in 
combination with a Cre-recombinase dependent dual reporter to label bIPCs with mCherry 
fluorescent protein and total electroporated cells with ZsGreen fluorescent protein, as 
previously shown by Tyler et al. (2013) (Fig.3). At 48hrs post IUE, ZsGreen-labeled cells 
will predominantly be aRGCs as SNPs have a shortened morphology compared to aRGCs, 
making them distinguishable. Neurons born from ZsGreen cells will also be labeled with 
ZsGreen. To confirm that inclusion of ZIKV into our IUE labeling strategy would not 
impact either infectibility or the efficiency of our plasmid reporters, we compared IUE 
outcomes of ZIKV alone, plasmid DNA alone, and ZIKV with plasmid DNA. To account 
for variations in fetal development when comparing NPCs in infected and control mice, 
one uterine horn was injected with ZIKV plasmid cocktail and the other injected with saline 





through the cervix to the control side or into the dam’s blood (Fig. 3). This model yields a 
successful infection of ZIKV via embryonic IUE in an immunocompetent mouse that 
allows for the labeling of various NPC populations in vivo across embryonic development.  
Precursor type consequences of persistent ZIKV infection 
 To investigate what NPC types are particularly targeted in acute infection, we next 
sought to understand how ZIKV infection progressed across cell types in longer time 
course studies. Tbr2-Cre and CAG-StopLight electroporated tissue was stained with NS2B 
in control and infected tissue at 1-6DPI. ZsGreen+/NS2B+ and mCherry+/NS2B+ 
populations were counted at each time point and all cell counts were normalized to the total 
number of electroporated cells to account for variability in the size of the electroporated 
field. Increased numbers of ZsGreen infected cells (ZsGreen+/NS2B+) were found at 1 and 
2DPI. However, at 3DPI, the number of infected mCherry cells (mCherry+/NS2B+) 
surpassed the number of infected ZsGreen cells. Infected mCherry and ZsGreen cell counts 
equalized at 4-6DPI as infected cell number decreased (Fig. 4). To further confirm cell type 
vulnerability, non-electroporated tissue was stained with Sox2 and Tbr2 at the same time 
points. Again, NS2B co-localized with more Sox2+ cells at 1 and 2DPI. At 3DPI, increased 
numbers of Tbr2+ mCherry cells co-localized with NS2B (Fig. 4). These findings suggest 
that aRGCs (ZsGreen labeled) are targeted by ZIKV initially and that bIPCs (mCherry) 
derived from these aRGCs gain active ZIKV infection either from cytoplasmic division or 





essentially cleared from the proliferative zones as neurogenesis proceeds as seen in NS2B 
staining (Fig 2).  
Discussion  
 Collecting infected and control embryos at days 1-6DPI and infecting at different 
timepoints in pregnancy allows for a thorough and in-depth explanation of ZIKV infection 
by timepoint and cell type. Our model demonstrates how the live, active form of ZIKV can 
be added to cell type specific IUE protocols to produce an effective model of viral infection 
in vivo without the need for interferon knock-out or inactivation of virus. Compared to 
previous studies that used higher concentrations of virus than would be delivered from a 
mosquito to a host, the concentration and strain of virus used here is most appropriate to 
study fetal infection in the Americas (Dudley et al., 2017). Additionally, by administering 
an appropriate concentration of ZIKV directly into developing mouse fetuses, we were able 
to comprehensively study multiple interacting components of brain development across 
time and stage of neurogenesis where we found less cell death and more morphological 
differences. It was found that aRGCs are infected preferentially at 1-3DPI while bIPCs 
were preferentially infected at 4DPI. This thorough time course study explains why some 
studies have found aRGCs to be the primary target while others have found IPCs to be 
ZIKV’s primary target. 
In addition to studying ZIKV, this model can be used to study the impact of any 
virus on brain development. For example, this model would serve to elucidate the effects 





groundwork for important future work regarding ZIKV infections in the brain as well as 
corticogenesis in the typically developing brain. This model will help us understand the 
long-term effects of brain infection so we can better prepare for prevention and treatment 








Figure 2. Fetal ZIKV infection spreads radially throughout the 
telencephalon. NS2B immunofluorescence in fetal brains infected 
intraventricularly on E12.5 with 10,000 FFU of ZIKV and collected one day 
post-infection (1DPI), 3DPI, and 6DPI. A) Vehicle control neocortical wall at 
3DPI. Scale bar: 60µm. B) Infected neocortical wall at 1DPI. Scale bar: 30µm. 
C) High magnification image of infected neocortical wall at 1DPI. Scale bar: 
10µm. D) Infected neocortical wall at 3 DPI. Scale bar: 60µm. E) Infected 
neocortical wall at 6DPI. Scale bar: 60µm. F) Presence of ZIKV was also 
measured with RT-qPCR in vehicle injected and ZIKV injected fetal brains at 1, 
2, 3, and 4 DPI. The vehicle injected brains had RT-qPCR cycle thresholds (CT) 
at or above 40 cycles, indicating no presence of virus. The number of 
amplification cycles necessary to detect ZIKV decreased with each day post 







Figure 3. ZIKV causes a decrease in fate mapped apical precursor cell 
number. A) Somatosensory cortex in control and infected brains was transfected 
with Tbr2-Cre + CAG-StopLight at E13.5 and collected 48hrs later (E15.5), 
labeling the apical progenitors in green and the basal Tbr2 lineage progenitors in 
red. B) 3DPI (E15.5) infected tissue with and (C) without IUE show no difference 
in NS2B labeling. Scale bars: 50µm. D) ZIKV RT-qPCR in IUE and non IUE 
infected brains across time show no difference in infection. E) Vehicle control 
electroporated with Tbr2-Cre and CAG-StopLight. Scale bar: 50µm. F) 3DPI 
(E15.5) infected brain electroporated with Tbr2-Cre and CAG-StopLight. Scale 
bar: 50µm. G) The percentage of ZsGreen+ cells in the total electroporated 
population was reduced in infected tissue compared to control (n = 4, 4). 
Statistical significance was calculated using unpaired t test (* indicates p<0.05) 












Figure 4. ZIKV infection appears first in apical precursors and subsequently in 
basal intermediate precursors following infection. A) Tbr2-StopLight fate mapping 
identifies temporal sequence of cell type infection. Brains were electroporated and co-
infected with ZIKV at E12.5 and collected 1-6DPI. Cell counts from confocal z-stacks 
indicate that ZsGreen+ apical precursors are preferentially infected at 1 and 2 DPI. At 3 
DPI, more mCherry+ basal precursors are infected than apical precursors. Thereafter, 
infection decreased in both cell types (n = 4, 4). Statistical significance was calculated 
using unpaired t test (* indicates p<0.05) and error bars represent standard error. B) 
Immunohistochemical staining for apical (Sox2) and basal (Tbr2) precursors 
demonstrates temporal spread of infection through the germinal zones. Brains were 
injected with ZIKV at E12.5 and collected 1-6DPI. Results indicate that Sox2+apical 
precursors are preferentially infected at 1 and 2 DPI. At 3 DPI, more Tbr2+ basal 
precursors are infected. In later time points, both cell types are infected equally (n=4, 
4). Statistical significance was calculated using unpaired t test (* indicates p<0.05) and 







Assessment of microencephaly in a murine model of ZIKV infection  
Introduction  
Microcephaly 
 Historically, microcephaly has been considered an important sign of neurological 
malformation and a predictor of future disability. Microcephaly is not a disease but rather 
a symptom or clinical sign of an underlying issue. The etiology can be genetic or 
environmental. Regardless of the etiology, microcephaly is always caused by insult to 
corticogenesis (Ross and Frias, 1977). In humans, the most susceptible period is peak 
neurogenesis, during the first half of the second trimester. It is thought that the severity of 
microcephaly may have more to do with the timing of the insult than to the nature of the 
injury (Dobbing et al., 1973). Microcephaly is defined as an occipitofrontal head 
circumference (HC) of 2 or more SD below the mean for age, sex, and ethnicity and can 
be used interchangeably with microencephaly which refers to brain size rather than HC. 
Microcephaly is relatively rare with between 2-3% of the population being affected (von 
der Hagen et al., 2017). As discussed in the introduction, microcephaly has a range of 
symptoms and severity. Microcephaly (2 SD below the mean) is associated with 
developmental delays, difficulty with coordination and movement, hyperactivity, and 
seizures. Severe microcephaly (3 SD below the mean) can have more severe effects such 
as blindness, cranial bone overlap with malformed facial features, difficulties swallowing 





primary and microcephaly developed postnatally is defined as secondary (Boonsawat et 
al., 2019). Although ultrasounds of fetuses exposed to environmental insult have revealed 
significantly smaller head size before birth, there is substantial evidence that fetuses 
exposed to ZIKV in utero are at increased risk of premature termination before birth 
(Boonsawat et al., 2019).  
 In primary microcephaly, the decrease in cortical growth is a result of abnormal 
regulation of mitotic division or increased cell death. Insults to later developmental stages 
such as myelination, synapse formation, membrane transport, or synaptic structural support 
result in secondary microcephaly (Boonsawat et al., 2019). Both primary and secondary 
microcephaly have been associated with insults to neuronal migration, DNA repair, and 
transcriptional regulation. In both primary and secondary microcephaly, the largest 
decrease in brain mass occurs in the cerebral cortex; the brain region responsible for 
attention, memory, awareness, language, and consciousness. This has major implications 
in the cognitive and intellectual deficits found in microcephaly patients. 
 The risk for intellectual disability increases as HC decreases. In children with a HC 
of 2-2.99SD below the mean, the risk for intellectual disability is 10.5%. In cases where 
the HC is between 3-3.99SD below the mean this risk increases to 51.2%. A HC of 4 or 
more SD below the mean is associated with a 100% chance of intellectual disability (Stoler‐
Poria et al., 2010). Children with reported microcephaly in utero that were followed 
through infancy did not always have a microcephaly phenotype postnatally. It is not yet 





measurement since pre-natal microcephaly is measured with calipers while most natal 
measurements are performed with flexible tape. Devakumar et al., (2018) assessed full-
term infants with microcephaly at birth. At 56 months, these children had poorer cognitive 
scores across multiple domains. In studies that followed pre-natal microcephaly into 
infancy and included infants whose HC returned to a sub-microcephaly difference from the 
mean, their findings corroborate previous work showing a negative linear correlation 
between HC and cognitive development (Walker et al., 2016). When comparing multiple 
variables such as HC in utero, HC at birth, length of pregnancy etc., in utero HC was the 
best predictor of cognitive function later in life (Davakumar et al., 2018). These findings 
indicate that even when the microcephaly phenotype is no longer found postnatally, 
children who had been reported to have microcephaly in utero might also benefit from 
therapeutic support to aid their development. 
 While there is no therapy for microcephaly as a clinical manifestation, there are 
treatments for many of the symptoms associated with impaired brain development. Clinical 
management of complications such as epilepsy, dysphagia, irritability, hyperactivity, 
hearing and vision loss, as well as supportive care for cognitive delays are available. In 
cases where microcephaly was comorbid with epilepsy, amino acid treatment was 
successful to reduce seizures caused by 3-phosphglycerate dehydrogenase deficiency (De 
Koning et al., 2002). Children with sporadic primary microcephaly associated short stature, 
delayed bone development, and low growth velocity had increased growth rates after 
treatment with exogenous growth hormones (Spadoni et al., 1989). In a case of secondary 





and successfully relieved some of the child’s symptoms (Undabeitia et al., 2011). In each 
case of microcephaly, the etiology needs to be determined in order to find an appropriate 
therapeutic. 
 Microcephaly can be caused by genetic or environmental reasons (Woods et al., 
2004, Faheem et al., 2015, Ashwal et al., 2009). Several genes have been identified as 
causes of primary hereditary microcephaly including MCPH1, WDR62, CDK5RAP2, 
CEP152, ASPM, CENPJ, CEP63, and STIL. These genes are generally expressed in the 
VZ during corticogenesis and impact proliferative ability. Interestingly, genes affecting the 
centrosome have also been implicated in primary hereditary microcephaly as well. These 
genes play diverse roles in DNA replication, centriole biogenesis, cytokinesis, and 
autophagy (Jayaraman et al., 2018). Alternatively, environmental insults to brain 
development may result in microcephaly.  
 Environmental causes of microcephaly include irradiation, chemical exposure, and 
viral infection. Three of the 5 original TORCH pathogens are known to cause 
microcephaly. TORCH originally stood for 
TOxoplasma/Rubella/Cytomegalovirus/Herpes but was later changed to Toxoplasma, 
Other, Rubella, CMV, Herpes simplex to include pathogens such as syphilis, varicella, 
mumps, parvovirus, and HIV. CMV, rubella virus, and Toxoplasma gondii are also 
associated with maternal transmission resulting in microcephaly (Frenkel et al., 2018). 
After the ZIKV outbreak in Brazil, it was proposed that ZIKV be added to the list of 





prototypical TORCH pathogen, rubella. They both present mild symptoms in adults such 
as rash or may be asymptomatic. In pregnancy, both are teratogenic and result in fetal 
malformations such as microcephaly and brain lesions (Shwartz et al., 2017). ZIKV also 
shares similarities with CMV in their neuroimaging results and presence of fetal brain 
calcifications (Parmar et al., 2012, Averill et al., 2015). Understanding how ZIKV leads to 
microcephaly is an important step in developing therapeutics for treatment and prevention. 
 ZIKV was first discovered to cause microcephaly in 2016. Since then fetal brain 
malformations associated with ZIKV infection have been expanded on. There are a variety 
of phenotypes that arise after pre-natal exposure to ZIKV hence the need for the term CZS 
to serve as an umbrella for the amalgamation of clinical indications possible. Structural 
changes caused by ZIKV infection include decreased brain volume, perturbed cranial 
morphology, brain anomalies such as calcifications, ocular anomalies, congenital 
contractures, intrauterine growth restriction, and decreased birth weight. Functional 
impairments include vision, hearing, movement, irritability, cognitive, and developmental 
delays (Besnard et al., 2016, Schuler-Faccini et al., 2015). The mechanisms behind CZS 
are not fully understood but many studies in different models have now shown that ZIKV 
affects NPCs in the developing germinal zone by decreasing proliferations and increasing 
cell death. Additional phenotypes such as impaired DNA replication, cytokinetic 
impairment, failed neuronal migration, and early differentiation have also been reported to 
contribute to ZIKV induced microcephaly (Li et al., 2016, Bhagat et al., 2018, Souza et al., 






One of the most important determinants of the eventual size of the cortex is the 
founder cell expansion phase. This is where the NEP population expands until molecular 
specification of aRGCs begins. aRGCs are commonly referred to as the stem cell of the 
brain as they give rise not only to all NPC types in the cerebral cortex but to neurons and 
glia. These aRGCs then provide necessary structure for newly born neurons to migrate out 
to the developing cortical layers which will be discussed further in Chapter 3 (Rakic et al., 
1988, Rakic et al.,1995).  
 One of the key determinants of cortical expansion is the mode of division. The 
decision of aRGCs to contribute to direct neurogenesis (giving rise to neurons directly) or 
indirect neurogenesis (giving rise to NPCs which then give rise to neurons) is still not fully 
understood but is known to largely impact the eventual size and complexity of the cerebral 
cortex. Understanding the mechanisms that drive the parent aRGC to produce direct or 
indirect neurogenic streams will greatly improve our understanding of corticogenesis and 
the assembly of eventual neural circuits.  
 Regardless of direct or indirect neurogenic streams, proliferation in the germinal 
zone of the developing brain is integral to corticogenesis. Previous studies have found that 
ZIKV inhibits proliferation of NPCs in non-human primates, rats, mice, slice culture, 
organoids, and cell culture (Dudley et al., 2017, Sherer et al., 2019, Li et al., 2016, 
Rosenfeld et al., 2017, Garcez et al., 2016, Tang et al., 2016, Smith et al., 2018, Liang et 
al., 2016). Decreased proliferation has been postulated to occur for a variety of reasons. 





strand breaks. They also reported impaired progression through S-phase which 
compromised the completion of host DNA replication. These results were specific to ZIKV 
and could not be recapitulated with dengue, or West Nile virus. This may be one of the 
adaptations seen in ZIKV to create a cellular environment favorable for its replication. 
Additionally, Souza et al., (2016) describe mitotic abnormalities caused by ZIKV. These 
include multipolar spindle, chromosome laggards, micronuclei and death of progeny after 
cell division. Their FISH analysis of chromosome 12 and 17 reveal increased frequency of 
aneuploidy, such as monosomy, trisomy and polyploidy. This is an interesting finding in 
relation to Down syndrome and the rates of intellectual disability found in patients with 
ZIKV induced microcephaly. Another related phenotype is the increased rate of terminal 
differentiation in ZIKV infected aRGCs. Instead of expanding the pool of aRGCs or giving 
rise to NPCs that will proliferate, infected aRGCs have been reported to have increased 
rates of early differentiation. This is likely another contributor to ZIKV induced 
microcephaly (Souza et al., 2016). While we know that proliferation is decreased in NPCs, 
we do not have any further information about what cells types specifically are impacted or 
why. Protection of the proliferative capacity of specific NPCs may provide the greatest 
possible protection against ZIKV induced microcephaly. 
Cell death 
 Apoptosis was coined by Kerr et al., (1972) to describe an intrinsic cell suicide 
program involved in the normal turnover of hepatocytes (Kerr et al 1972). Apoptosis is 





wall while the cellular contents are condensed and broken down. Cells marked for 
apoptosis are ingested by neighboring cells without initiating an immune response (Cohen 
et al., 1997). This is in opposition to necrosis (uncontrolled cell death), which induces 
significant inflammation due to cell lysis and leakage (Cohen et al., 1997). In the nervous 
system, apoptosis occurs in neurons, glia, and NPCs. It is estimated that 50% or more of 
neurons in the nervous system are eliminated via apoptosis (Oppenheim 1981, Burek & 
Oppenheim 1999). Apoptosis plays an important role in optimization of synaptic 
connections, removal of unnecessary neurons, and pattern formation to create efficient 
neural networks in the brain (Burek & Oppenheim 1999).  
 Intracellular and extracellular apoptotic signals activate a group of apoptotic-
specific cysteine proteases called caspases (Thornberry & Lazebnik 1998). Caspases are 
necessary for chromatin condensation, DNA fragmentation into nucleosomal fragments, 
nuclear membrane breakdown, and the formation of apoptotic bodies that are key 
identifiers of apoptosis and thus are commonly used as a marker for apoptosis. 
 Studies investigating the role of cell death in ZIKV induced microcephaly have 
used cleaved caspase 3 or TUNEL to discover the amount of cell death caused in different 
strains of ZIKV (Tang et al., 2016, Smith et al., 2018, Liang et al., 2016). It has been shown 
that accumulated mutations in the non-structural proteins of ZIKV have actually decreased 
the amount of cell death caused in the African strains versus the Asian/American strains 
(Simonin et al., 2017). It is hypothesized that the reason for this is increased immune 
evasion, where the modern strains of ZIKV evoke more mild immune responses than their 





cells more so than if the host cells were cleared from the brain (Simonin et al., 2017). While 
immune evasion has likely decreased the amount of cell death caused when comparing 
MR766 against PRVABC59 for instance, apoptosis is still significantly increased in 
infected brain tissue compared to control. This increase in cell death undoubtably 
contributes to microcephaly. 
 Studying proliferation and cell death in an in vivo model with a modest titer of 
active, modern ZIKV (PRVABC59), is important in fleshing out the differences between 
cell types in their vulnerability to disrupted mitosis, and allows for longitudinal study of 
proliferation, cell death, and microcephaly to better inform the etiology of ZIKV induced 
microcephaly. Here we use the model shown in Chapter 1 to assess if microcephaly is 
recapitulated. An in vivo model of microcephaly will allow for investigation of the 
contribution of proliferation, apoptosis, and cell type differences in vulnerability to 
corticogenesis across development. 
Results 
Time course of ZIKV-induced microencephaly 
 To assess if our mouse model of embryonic ZIKV infection recapitulates the 
microencephaly phenotype found in humans and other models, rostral-caudal and medial-
lateral dimensions of the telencephalon were measured. Figure 5 shows a micrograph of 
control (left) and infected (right) brains that were measured medial-laterally and rostral-
caudally to assess differences in brain size. By measuring brain size rather than head size, 





microencephaly, rather than microcephaly. The medial-lateral and rostral-caudal 
measurements in brains that stained positive for ZIKV antibody using IHC were compared 
to saline-injected littermates. Microencephaly (>2SD) was found at 1-6DPI when fetuses 
were injected at E12.5 (Fig. 5). Fig. 5C, 5D displays a microencephaly phenotype at 1DPI 
when injected at E12.5, 13.5, 14.5, and 15.5 and at 2DPI when injected at E12.5, 13.5, and 
14.5 (Fig. 5E, 5F). These thorough and age matched experiments allow for assessment of 
ZIKV infection spanning neurogenesis and at infection times in the second and third 
trimester of pregnancy. Additionally, cortical thickness, measured at each time point after 
E12.5 infection was consistently decreased from 1DPI-birth (Fig. 5H). The approximately 
100µm decrease in gross brain size was also found in cortical thickness, indicating that the 
decrease in brain size is primarily due to impaired cortical expansion (Fig. 5H). 
Surprisingly, ZIKV-induced decrease in brain size was not dependent on the age at 
infection (Fig. 5C-E).  
Cell death 
 To determine if the observed decrease in cortical thickness was due to ZIKV-
induced cell death, infected and control tissue was stained for cleaved caspase 3 (CC3) to 
mark cells labeled for apoptosis. After 2DPI of ZIKV exposure, cell counts showed a 
29.3% increase in CC3+ apoptotic cells in the cortical wall. To test if cell death increased 
over time after infection, 3 and 4DPI control and infected brains were assessed as well. 
Interestingly, rates of apoptosis did not change over time, showing a consistent increase in 






 Ki67 and phospho-histone H3 (Ph3) were then used to assess changes in 
proliferation in infected and control brains. Decreased numbers of Ki67+ and Ph3+ cells 
were found in ZIKV infected tissue within the VZ and SVZ compared to non-infected 
controls (Fig. 7). These findings suggest that our fetal ZIKV infection model results in 
increased cell death and a reduction in the number of proliferating NPCs during embryonic 
neural development. Both of these disruptions are likely to contribute to the observed 
microencephaly phenotype.  
Cell type specific deficits in proliferation 
 To assess whether ZIKV affected the proliferative capabilities of specific cell types, 
E12.5 embryos were electroporated with Tbr2-Cre and CAG-StopLight and collected at 
2DPI. We found a 40% decrease in the number of apical ZsGreen+/Ph3+ co-labeled cells 
in infected tissue compared to controls (Fig. 7). In contrast, mCherry/Ph3+ cell number 
percent decrease after infection was 18.2%, a smaller but significant change (Fig. 7). To 
test the hypothesis that aRGCs were more affected than bIPCs at 2DPI, non-electroporated 
ZIKV-infected brain samples were stained for Sox2 and Tbr2, respectively. While both 
cell types showed decreased numbers of Ph3+ cells at 2DPI, Sox2+ cells were particularly 
impacted with a 60% decrease compared to the 28.6% decrease found in Ph3+/Tbr2+ cells 
(Fig. 8). These experiments confirm that aRGCs are targeted by ZIKV early in infection 






 The model described in this work allowed for in vivo time course studies that probe 
the progression of ZIKV infection over the course of 6 days of pre-natal development. This 
is the longest in vivo time course study of ZIKV effects in a model to date. This method 
enabled the tracking of the microencephaly phenotype over time that uncovered some 
surprising findings. It was found that severity of microencephaly was consistent across DPI 
1-6. One explanation for this is that aRGCs are targeted initially, creating a severe depletion 
in proliferation which is then compensated for by the remaining aRGCs and other NPC 
types. Alternatively, as soon as new aRGCs are born and able to proliferate, cortical 
expansion continues at the same rate, unable to compensate for the initial volume loss. It 
was also surprising that the microencephaly phenotype was not impacted by the age of the 
animal at the start of infection given that human data shows increased severity of the 
infection that happened earlier in pregnancy (Schuler-Faccini et al., 2016, Johansson et al., 
2016). This discrepancy is likely due to the differences in human and murine immune 
development. Unlike humans, mice do not have a fully developed immune system until 
one week after birth. Without having differences in the expression of interferon, there may 
be less of a difference in susceptibility between E13.5-E16.5. Another factor that may be 
important in susceptibility is the number of aRGCs since our work provides evidence that 
they are the most vulnerable to initial infection. The E13.5-16.5 time frame covers the peak 
of neurogenesis (around E15). Some discrepancies would have been expected between 
E13.5 and 16.5, however, it may be possible that the difference in aRGC number is not 





the IUE timepoints even earlier would have helped further explain the progression of ZIKV 
infection in its ability to cause microencephaly. Additionally, a proliferation compensation 
mechanism may be operative. This possibility is an interesting avenue for future study 
given the role that cell-to-cell contact plays in proliferation. If there are fewer aRGCs in 
the VZ, the decreased pressure on cell contact could allow for increased proliferation in the 
unaffected cell populations. To test this, double IUE labeling with Prc1 and MFAP2 
(discussed in chapter 4) could be used with Ki67 staining to assess proliferation 
compensation.  
 Immunostaining of Ph3 and Ki67 were done by 100-micron bin to have a rough 
assessment of proliferation in the VZ, SVZ, and cortical plate. This measurement assessed 
proliferation differences between apical and basal NPCs. We found that proliferation was 
decreased in the first and second bin from the ventricle indicating both apical and basal 
cells proliferative capacity was decreased in infected tissue compared to controls. To test 
this more specifically, we used Tbr2-Cre and CAG-StopLight IUE co-labeled with Ph3 as 
well as a secondary measure of Sox2, Tbr2, and Ph3 immunostaining. These cell type 
specific experiments showed the greatest decrease in proliferation was in Sox2+ apical 
NPCs. These experiments added to the specificity of the proliferation by bin experiments 
while corroborating the findings that both apical and basal NPC proliferation was 
decreased in ZIKV infected tissue. 
 Cell death was measured using cleaved caspase 3 immunostaining as was done in 
previous studies (Simonin et al., 2016, Li et al., 2016, Smith et al., 2018) Perhaps because 





less cell death was found than has been reported previously. In fact, when counting CC3+ 
cells in 20x magnification 20-micron thick sections as typically done in my cell counts, 
cell death was not significantly increased. To make sure that the CC3 staining was working, 
tissue with known cell death measurements were used as a control where similar numbers 
of apoptotic cells were found in my hands compared to previous studies. For this reason, 
CC3+ cells were counted in the entire cortical wall through the ocular at 10x magnification. 
Counting the entire cortical wall from the ventricle to the pia and from midline to the most 
posterior surface resulted in statistically significant differences between infected and 
control tissue. While CC3 immunostaining only captures a subset of apoptotic cells and 
there are likely many more cells in the process of apoptosis than are counted in CC3 stains, 
the CC3+ cell numbers in this study are less than what is seen in similar studies who used 
a higher titer of virus. The fact that infection can be detected with 103 FFU, with other 
major phenotypes other than cell death, may be a benefit to the experimental design in that 
it allows for inspection of more subtle phenotypes such as perturbations to the 











Figure 5. ZIKV decreased forebrain growth regardless of age of infection. Litters 
were injected at E12.5, 13.5, 14.5, 15.5 and collected 24hrs later. A) Medial-lateral and 
(B) rostral-caudal brain measurements were significantly decreased after ZIKV 
infection starting at 1DPI. The microencephaly phenotype was not dependent on 
developmental age in C) Medial-Lateral measurements at 1DPI or D) Rostral-Caudal 
measurements. Brains injected at E12.5, 13.5, and 14.5 and collected 48hrs later also 
showed the same microencephaly phenotype in E) Medial-lateral and F) Rostral-Caudal 
measurements. G) Micrographs of example vehicle and ZIKV infected brain from litter-
matched embryos at E14.5 (2DPI). H) Cortical thickness (microns from ventricle to pial 
surface) in 20x images of coronal brain sections. Control and infected brains were 
injected at E12.5 and collected 1-6DPI. I) Representative image of saline injected 
control neocortical wall from the contralateral uterine horn collected at E13.5. J) Image 
of ZIKV injected control neocortical wall from the contralateral uterine horn collected 
at E13.5 (1DPI). Statistical significance was calculated using unpaired t test (* indicates 









Figure 7. ZIKV infection reduced proliferation in the telencephalic germinal 
zones. A) Ki67+ average cell number counted in 100-micron bins (bin 1 closest to 
ventricle, bin 4 closest to pia) in embryos injected at E12.5 and collected at E14.5. 
Bins 1 and 2 which overlap most with the VZ and SVZ have significant decreases in 
proliferating cells following ZIKV infection. B) Representative single plane image 
of control on left and (C) infected on right. D) Ph3+ average cell number by depth 
in bin. Bins 1 and 2 which overlap most with the VZ and SVZ have significant 
decreases in proliferating cells following ZIKV infection. E) Representative single 
plane image of control on left and (F) infected on right (n = 4, 4). Cell numbers were 
counted in each single plane image of 20-micron z-stack images and summed for 
each bin. Statistical significance was calculated using unpaired t test (* indicates 









Figure 8. Genetic fate mapping in proliferative cells reveal cell lineage-
specific effects of ZIKV infection. A) Tbr2-Cre CAG-SL electroporated brains 
were collected after 48hrs (IUE on E12.5). Control and infected brain sections 
were stained for   Ph3. The number of   Ph3+ Tbr2 lineage (mCherry+) cells was 
decreased by ZIKV infection. B) The number of   Ph3+ Non-Tbr2 lineage 
(ZsGreen+) cells was decreased by ZIKV infection. E14.5 control and infected 
brain sections were immunostained for   Ph3 and Tbr2. C) The number of   Ph3+, 
Tbr2+ cells was decreased by ZIKV infection. D). The number of   Ph3+, Sox2+ 
cells was substantially decreased by ZIKV infection. Statistical significance was 
calculated using unpaired t test (* indicates p<0.05) and error bars represent 
standard error. A sample size of 4 was used in each condition. E) Illustration of 











 In pursuit of understanding the etiology of microcephaly, one must consider the 
cytoarchitecture of the developing neocortex. Each of the NPCs contributes to 
corticogenesis in a unique way. The unique morphology and transcriptional profile of each 
NPC class makes them distinguishable from one another and allows for the study of 
respective contribution to neurogenesis from each cell class. As seen in the illustration in 
Fig. 1B, bIPCs are located in the SVZ and can either have a multipolar or a radial 
morphology with an apical process but no basal process. Having the opposite morphology, 
bRGC only have a basal fiber in their radial morphology and are located in the IZ. aIPCs 
are located in the VZ and have a shortened radial morphology (also referred to as SNPs) 
(Gal et al., 2006), where their basal process does not extend to the pial surface like their 
neighbors, the aRGCs. aRGCs are located in the VZ and have a radial morphology with an 
apical and basal fiber (Rakic, 1972). 
Corticogenesis 
 While there are some differences in corticogenesis across mammalian species, 
many of the key aspects remain the same. Differences in human and mouse brain 





expansion phase where founder cells proliferate vastly to increase the area of the 
developing VZ. Differentiation into aRGCs initiates symmetric and asymmetric divisions 
leading to neurogenesis. As neurogenesis progresses, the VZ cell numbers start to deplete 
and gliophilic migration into the cortical layers begins. Gliophilic migration is the process 
of attraction and attachment of a newborn neuron onto the basal process of an aRGC. These 
neuroblasts climb the basal fiber until they reach their destination in the cortex. Only then 
do they unattached from the basal fiber to become independent of the aRGC. Neurons 
migrate in an inside out manner where neurons born early inhabit the deep layers and late 
born neurons inhabit the outer layers of the cortex. Cortical layers 2-6 are formed by 
neurons climbing the basal fibers of the aRGCs in the VZ, to find their final destination in 
the cortical wall, first by forming the preplate in rodents and subsequently splitting the 
preplate into the deep subplate and superficial marginal zone (neocortical layer 1) (Hartfuss 
et al., 2001, Miyta et al., 2001, Noctor et al., 2002, Tamamaki et al., 2001, Malatesta et al., 
2000). As more neurons are born, cortical layers 2-6 are generated in an inside out manner 
in all mammalian species (Rakic et al., 1975). These key aspects of mammalian 
neurogenesis are essential to the formation of a healthy brain. 
Migration 
 Successful neuronal migration requires both intrinsic and extrinsic factors. 
Directional control of migration is determined by the leading process of the new born 
neuron, the availability of aRGC scaffolds, and secreted factors (Marín et al., 2010). 
Semaphorin 3A (Sema3A) attractant for example, is expressed in descending gradients 





upper cortical layers (Chen et al., 2008). The orientation and directionality of cell migration 
can be classified into two basic axes, radial which is perpendicular to the pial surface and 
tangential which is parallel to the pial surface. These different types of migration use glial 
processes (gliophilic) or neuronal axons (neurophilic) as their substrates respectively 
(Rakic, 1990). 
 Migration from the VZ towards the pial surface of the developing cortical wall is 
termed pial-directed radial migration. This is the more common type of radial migration, 
with pyramidal cells of the cerebral cortex being the classical example of pial-directed 
radial migration. Though further research discovered that migration may occur radially 
inward. For example, cerebellar granule cells and pontine nuclei neurons have been shown 
to switch their direction in the SVZ/VZ before embarking on radial migration (Kawauchi 
et al., 2006, Tabata and Nakajima, 2003).  
 Tangential migration can be directed or non-directed. In directed migration, 
interneurons migrate from their birth place in ganglionic eminence to the cerebral cortex 
where they will create networks with excitatory neurons. Neurons such as cerebellar 
granule cell precursors, neurons of the pontine nuclei, Cajal Retzius cells, neurons of the 
lateral reticular nucleus, and neurons migrating from the telencephalon to the olfactory 
bulb also use directed tangential migration (Nóbrega-Pereira and Marin, 2009, Bielle et al., 
2005, Gil-Sanz et al., 2013). While Cajal-Retzius cells migrate tangentially from the 
pallium, they colonize the surface of the entire cortex and release reelin, which guides 
radial migration of the projection neurons of the neocortex (D'Arcangelo et al., 1995, 





 Non-directed tangential migration is an interesting way for inhibitory interneurons 
to travel in all directions of the tangential plane circuits in need of inhibitory control. For 
example, in what is referred to as a random walk, interneurons migrate in all directions 
within the marginal zone. They change their direction repeatedly and migrate in different 
directions until settling into their final position (Tanaka et al., 2009). This tangential 
migration of inhibitory interneurons into the cortical wall is essential in the balance of 
inhibition and excitation in the brain. 
 Research on ZIKV infected tissue showed that ZIKV disrupts the aRGC scaffold 
required for neuronal migration in the cerebral cortex (Rosenfeld et al., 2017).  IF of 
organotypic brain cultures were used to find that ZIKV infection decreased neuronal 
migration as reflected by a lower percentage of electroporated cells reaching the most 
superficial layers of the neocortex (Rosenfeld et al., 2017). Chimelli et al, (2016) also 
describe defective migration in ZIKV infected tissue. These findings lead to the hypothesis 
that migration failure due to a dismantled aRGC scaffold may be contributing to ZIKV 
induced microcephaly. 
Results 
ZIKV infection alters neocortical cytoarchitecture: Analyses of IUE labeled cells 
 The labeling of aRGCs and bIPCs with the dual color fluorescent protein reporter 
allows simultaneous fate mapping of two types of precursors and visualization of changes 
in whole cell morphology in response to ZIKV infection. In particular, we found noticeable 
patterns of disorganization in the basal processes of aRGCs that stretch to the pial surface 





during development and may elucidate the mechanism behind decreased migration after 
infection (Chimelli et al, 2016). Rosenfeld et al. (2017) also described perturbed 
cytoarchitecture using organotypic mouse brain slice cultures electroporated with CAG-
GFP. This phenotype has not yet been quantified. To test if the number of fibers had 
decreased after infection, we counted the number of end feet reaching the pial surface in 
control and infected tissue at 2DPI, normalized to the number of IUE+ cells present. While 
a decrease in aRGC fibers/endfeet may be due to the decrease in aRGC numbers after 
infection, our fate mapping studies showed only an 18.2% decrease in apical ZsGreen cells 
at 2DPI (Fig. 3G). Our endfeet counts indicate a 60% decrease in aRGC basal fibers, 
indicating that the interrupted basal process phenotype is independent of the decreased 
numbers of aRGCs. Loss or retraction of aRGC basal fibers from the superficial cortical 
layers may lead to neuronal migration defects and ultimately cause decreased cortical 
thickness and hypoplasia.  
DiI Analyses support findings of perturbed basal fibers 
 To confirm the loss of aRGC basal processes, the lipophilic dye DiI was applied to 
the exterior surface of control and infected brains after the removal of the meninges. 
Allowing two weeks for passive intramembranous diffusion the density of DiI labeling was 
decreased in the VZ and SVZ of infected tissue. Neural projections and somata were 
notably labeled in the cortical plate of infected tissue but the aRGC basal fibers were 
sparser than in vehicle control brains (Fig. 9). To quantify this difference, the DiI intensity 
was measured in the VZ and in the area of greatest brightness directly above the VZ called 





intensity to account for differences in DiI penetration. Infected tissue showed a ~50% 
reduction in DiI intensity (Fig. 10). Depletion at E15.5 would negatively impact peak 
neurogenesis. This is likely to impact both deep layer and upper layer neurons given that 
this timepoint is not specific to early or late neurogenesis. Together, the IUE and DiI studies 
demonstrate that ZIKV infection causes disruption to the neocortical cytoarchitecture by 
disrupting aRGC basal processes.  
Discussion 
 Previous studies have reported that they observed perturbed basal fibers but have 
never quantified this phenotype, likely due to the technical difficulties involved in counting 
fibers. Tbr2-Cre and CAG-StopLight electroporated infected and vehicle control tissue 
were used to image 20x magnification 20-micron thick z-stacks so that green fibers could 
be counted. Green fibers in this experiment would label apical cells and red fibers would 
be in the Tbr2+ basal cell lineage and could work to discriminate between the cell types of 
basal fibers. It was thought that the basal fibers could be traced back to the somas in the 
VZ using orthogonal 3D images. This approach was not feasible due to the density of 
electroporated cells in the cortical wall. For this reason, ZsGreen+ end feet at the pial 
surface were counted in z-stacks and normalized to the total number of electroporated cells 
to account for differences in the size of the electroporated field. The benefit of this method 
is that basal progenitors are mCherry+ and excluded from the analysis, making our counts 
more specific to aRGCs. The pitfall, however, is that neurons born from the aRGCs would 
also be ZsGreen+. It is likely that some of the end feet counted include neurons. Hence this 





 To avoid the problems with tracing aRGC basal fibers to their somas in the VZ, DiI 
was used as a lipophilic tracing method in a similar method to Gal et al., 2006. When 
applied to the pial surface of the brain, only VZ localized somas whose end feet are intact 
at the pial surface will be labeled. This method also produces extremely dense labeling, 
making individual cells difficult to count accurately, hence the use of intensity. One 
limitation of this method is that if the crystals are not evenly applied, some regions of the 
brain will be densely labeled while other are sparse. To avoid making conclusions about 
ZIKV infection from uneven sparsity of labeling, the DiI was dissolved in ethanol, poured 
into a petri dish, air dried until only a crystal lattice remained, and then brains were rolled 
in the lattice to create an even coating DiI. To account for any remaining differences, DiI 
intensity in the VZ was normalized to the brightest area directly above so that differences 
in intensity were not a result of poor labeling.  
 While both of these techniques have their limitations, both show significant 
decreases in healthy cytoarchitecture in infected tissue compared to vehicle control. This 
decrease in basal fibers is likely to cause the observed neuronal migration deficit (Chimelli 
et al, 2016). When newborn neurons fail to migrate, they are cleared from the brain. This 
may be the reason for the observed increase in neuronal cell death seen in postnatal mouse 
experiments (Fujita et al., 2014, Rosenfield et al., 2016, Smith et al., 2018, Simonin et al., 
2016, Li et al., 2016). Additionally, Jinnou et al., (2018) reported that despite aRGC basal 
fibers diminishing in postnatal development, when an insult to the brain occurs, increased 
numbers of aRGC fibers remain as a means of repair by allowing newborn neurons to 





aRGCs) was transplanted into injured brains, migration and maturation of neuroblasts 
increased. Functional improvements in impaired gait behaviors were also seen after 
transplantation. This research suggests that even in postnatal development, aRGC basal 
fibers are necessary for migration and play a role in recovery and neuronal regeneration in 
neonatal brain injuries (Jinnou et al., 2018). Exogenously induced scaffolding should be 









Figure 9. Forebrain ZIKV infection disrupts radial scaffolding of the 
telencephalic wall. Brains were electroporated with Tbr2-Cre + CAG-StopLight 
and either vehicle or ZIKV at E13.5 and collected 48hrs later (E15.5). A) ZIKV 
disrupts cytoarchitecture. Example of maximum projection z-stack of 
electroporated infected tissue at 2DPI, showing normally developing (yellow 
arrow) and perturbed basal processes (red arrow). Scale bar: 20µm. B) Basal fiber 
end foot number is decreased in infected tissue. Cells were counted in the 
electroporated region of somatosensory cortex in 3D image stacks. The number of 
end feet was normalized to IUE+ cell number and was significantly decreased in 
infected tissue (n = 4, 4). Statistical significance was calculated using unpaired t 








Figure 10. DiI labeled aRGC basal fibers of control and infected brains reveal 
disrupted basal fiber morphology after ZIKV infection. DiI was applied to the 
surface of E15.5, 2 DPI control and infected littermates and was allowed to diffuse 
for 2 weeks at room temperature. A) DiI applied to the pial surface of the cortex 
labeled cell membranes in the VZ by diffusion down basal fibers. DiI labeling in the 
vehicle injected cortex shows complete labeling of aRGC palisade from the pial to 
the ventricular surface. B) Inset from A illustrates normal DiI intensity. Scale bar: 20 
µm. C) Basal fibers are disrupted in infected tissue. DiI labeling in 2DPI infected 
cortex reveals many areas of neocortical wall with patchy diffusion; somata and 
neurites are labeled in the IZ and CP but very little DiI label is found in the VZ and 
SVZ. D) Inset from C illustrates sparse labeling of fibers in the VZ and SVZ of 2DPI 
cortex. Scale bar: 20 µm. E) DiI intensity in VZ/SVZ was normalized to the brightest 
intensity in the IZ directly above measurement taken in the VZ/SVZ. The VZ/SVZ 
intensity was significantly decreased in infected tissue (n = 4, 4). Statistical 
significance was calculated using unpaired t test (* indicates p<0.05) and error bars 







Heterogeneity of aRGCs and differential vulnerability to ZIKV 
Introduction 
 Cortical expansion is a complex developmental process with multiple factors to 
consider. Here we have considered the impact ZIKV has on birth and proliferation of 
various NPC types, cell death, early differentiation, cytoarchitecture, and neuronal 
migration. Additional aspects include cell fate, sub-population heterogeneity, genetic 
control, and evolutionary adaption that leads to a more advanced and gyrated human brain. 
There is still much to be discovered about corticogenesis. In fact, the Radial Unit 
Hypothesis (RUH) first described by Pasko Rakic in 1988 continues to serve as a useful 
framework for understanding the mechanisms of cortical development. The RUH states 
that the cerebral cortex develops in cortical columns, or 'radial units', from distinct sections 
of aRGCs in the VZ. This idea of interacting radial units is based on the repeating 
functional circuits across the cortex where additional functional areas can be added based 
on proliferation in the VZ and SVZ (Rakic, 1988). 
 Intimately related to the RUH is the protomap hypothesis, which states that each 
radial unit has a unique signature that will predict the functional specification of the unit. 
As discussed previously, aRGCs born in the VZ will give rise to post-mitotic neurons that 
migrate radially to form the cortical plate in the classic 'inside-out' manner beginning with 
the deep cortical layers. Once they have reached their final destination, neurons will form 
circuits with other cortical and subcortical neurons. This often leads to a columnar shape 





investigation into the molecular profiles of separate units. So far, these profiles remain 
elusive but recent scRNAseq studies using mouse and human brain samples across 
different regions of the cortex and at different developmental stages have found regional 
differences which may be in support of the protomap hypothesis (Ugomma et al., 2020). 
These types of scRNAseq experiments with in vivo validation are not only essential to 
discovering functional differences in NPCs as they contribute to corticogenesis but also 
inform our definition of cell type versus cell state.  
 As discussed in the chapters previous, there is known heterogeneity in NPC 
populations where their morphology, transcriptional profile, and location of mitosis have 
been well documented. This is the case for aRGCs, bRGCs, aIPCs, and bIPCs. The 
heterogeneity within each of these groups, however, is only beginning to be described. 
Labeling sub-types of NPCs based on their transcriptional profile will allow for the study 
of their contribution to corticogenesis. The similarities in how NPCs contribute to 
corticogenesis across mammalian species was discussed in Chapter 3. There are, however, 
key differences between mouse and human brain development that give rise to a larger 
cerebral cortex, gyrification, and increased cognitive abilities.  
 One of the major differences between rodents and humans is gyrification. Without 
the gyri and sulci that greatly increase the area of the brain, the lissencephalic or “smooth 
brained” rodent, has a smaller cortex and decreased cognitive performance. The 
underpinnings of gyrification are not fully understood. There are interesting mysteries to 
gyrification such as the reproducibility of specific folds across people and even some 





and temporal pattern of development (Welker 1990; Borrell and Reillo 2012). These 
primary sulci have been found to be highly heritable, appear earliest in gestation, and are 
strongly associated with underlying cytoarchitecture. Secondary sulci are shallower and 
more variable (Lohmann et al. 1999). There are 3 main hypotheses for the production of 
gyrification; 1) The axonal tension hypothesis, the radial expansion hypothesis, and 3) 
differential tangential expansion hypothesis. 
 The axonal tension hypothesis posits that tension created by axons in 
interconnected brain regions is enough to drive gyrification. Prolonged force applied by 
axons would pull connected cortical regions together to form gyri while areas that are not 
well connected would form sulci. Computational models fail to recapitulate this model with 
numerical values for force (Xu et al., 2010). Additionally, it has been shown that 
gyrification can be experimentally induced in the embryonic mouse in the absence of 
axonal connections (Rash et al., 2013). 
 In the radial expansion hypothesis, uneven proliferation in the brain causes gyri and 
sulci. When growth in the subgranular layers exceeds that of the infragranular layers, 
buckling results in gyrification. This idea of mechanical buckling leading to folds in the 
cortical surface dates back to Retzius in the late 19th century with many theories of 
gyrification being loosely tied to the hypothesis (Ronan et al., 2014). 
 The most recent hypothesis for gyrification is called the theory of differential 
tangential expansion. This hypothesis states that gyrification is the result of different 
tangential expansion rates between different cortical areas such as the VZ during the 





distinct cortical regions causes increased pressure. Non-uniform pressure leads to buckling 
in stable regions such as primary sulci because of the underlying cytoarchitecture (Ronan 
et al., 2014). 
 These three hypotheses share the commonality that gyrification is driven by 
proliferation of NPCs in the developing cortex. Prolonged neurogenesis, the increase in 
number and type of progenitor cells, and the conical migration trajectories of neurons to 
the developing cortex all play an important role in gyrification. Evolutionary differences 
between gyrencephalic and lissencephalic animals include the presence of the outer 
subventricular zone (oSVZ) and increased numbers of bRG in humans. This addition in the 
human brain leads to greater neurogenesis from the proliferating bRGs and increased 
cognitive ability. However, a singular source has not been found that can on its’ own 
explain gyrification. A combination of factors is likely necessary for the control of 
gyrification (Borrell and Reillo 2012). For example, bRG can be found to impact 
gyrification in studies looking at certain brain regions in certain species, while other studies 
refute these findings (Stahl et al., 2013, Reillo et al., 2011, Rash et al., 2013, Poluch and 
Juliano, 2013). It is difficult to make strong conclusion with each study being carried out 
in different species, in different parts of the brain, and at different developmental stages 
(Nonaka-Kinoshita et al. 2013). These studies do, however, demonstrate the variable 
impact of bRG and their role in gyrification which for now seems to be the result of 
tangential cortical expansion, which is itself influenced by multiple factors, which act to 





 The idea of multiple factors coming together to tightly regulate gyrification fits with 
observations of how genes and transcription factors (TFs) regulate brain development. As 
mentioned previously, proliferation is regulated by a number of genes, that when mutated, 
lead to malformations of the brain. Rash et al. (2013) showed that manipulation of FGF2 
can induce folding and promote aRGC self-renewal, leading to an increase in tangential 
cortical expansion. Other factors which prevent apoptosis may be used to artificially 
maintain the progenitor pool, similarly, increasing expansion (Haydar et al. 1999). As 
discussed in Chapter 2, dysregulation of genes that modulate neuronal differentiation, 
apoptosis, or migration attenuate surface expansion. For example, LIS1 and DCX regulate 
radial migration and have been linked to lissencephaly (Sapir et al., 1999, Taylor et al., 
2000, Borrell and Reillo, 2012). A TF that regulates progenitor proliferation, EMX2, has 
been linked to schizencephaly (clefts in the cortex) which cause severe effects such as 
paralysis, seizures, microcephaly, developmental delays, and cognitive impairments 
(Walsh et al., 1999). The gene ARGAP11B, that is expressed in human RGCs and is known 
to increase basal NPC proliferation, has been found to create gyri and sulci when 
exogenously expressed in developing mice (Florio et al., 2015). This shows the important 
role of genetic regulation in gyrification.  
 Genetic control of the quantity and type of NPC in the developing brain 
significantly impacts proliferation and neuronal output. Evolutionary expansion of the 
human neocortex is due to increased numbers of bRG in the oSVZ whose proliferation 
leads to increased numbers of neuroblasts that mature as integrated neurons in the human 





brain compared to the mouse and result in higher cognition (Kriegstein et al. 2006; Lui et 
al. 2011; Reillo et al. 2011). Together, NPC type, NPC proliferative capacity, structural 
pressures in the brain, and genetic regulation play important roles in the evolutionary 
differences between species.  
 While we know that aRGCs generate cortical neurons either directly or indirectly, 
it is still unclear how a homogenous group of aRGCs give rise to diverse neuron types in 
each of the cortical layers whose functional, morphological, and electrophysiological 
properties all differ. One hypothesis is that aRGCs undergo temporal fate restriction. 
Evidence for this comes from transplantation studies where aRGCs generated neurons 
appropriate for their birth date even when explanted to a new environment (McConnell et 
al., 1991). Temporal control certainly seems to play a role in the fate of neuronal daughter 
cells, however the diversity of 50+ excitatory neurons is yet to be explained. A possible 
second role for the precursor heterogeneity in brain development is a direct contribution to 
neuronal diversity.  
 With advances in scRNAseq, new studies are finding that aRGCs in different 
regions of the brain exhibit transcriptional similarities to one another but with key 
differences based on their location. This is an interesting finding given that the same aRGC 
type give rise to extremely diverse neuron types depending on their location in the brain 
(Ugomma et al., 2020). Another recent scRNAseq experiment showed that adult neurons 
maintained transcriptomic signature of their mother cell (Heavner et al., 2020). In fact, it 
has been shown that neurons born at the same time from aRGCs and IPCs will inhabit the 





properties, and complexity of dendritic arbors (Tyler et al., 2015, Guillamon-Vivancos et 
al., 2018). These results indicate that neurons are primed with information guiding their 
fate based on their parent cell identity. Additional evidence for priming was shown in Li et 
al., (2020), where Tbr2 transcript was present without Tbr2 protein expression in the parent 
cells of Tbr2 protein positive NPCs, indicating transcriptional priming as a mechanism of 
fate determination.  
 It is thought that the reason behind NPC variety is to contribute to cortical 
expansion and possibly gyrification but also to increase the diversity of neuron populations. 
One of the rate-limiting steps in this line of research is the development of molecular 
markers for in vivo analysis of NPC sub-types. Only when the true scale of precursor 
heterogeneity is elucidated can comprehensive studies investigating the role of individual 
cell types in cortical development and evolution be established. By understanding the 
diversity of each NPC and respective contributions to neurogenesis at various stages in 
development, the symptoms of CZS that occur heterogeneously based on severity and time 
of infection can be better understood. Here, scRNAsequencing data from mouse cortical 
wall (Li et al., 2020) is used to create molecular markers and test the hypothesis that there 
are two separate classes of aRGCs in the developing cortex that may have differential 







  In ZIKV infected tissue, a proportion of aRGC fibers were perturbed while others 
developed normally. This finding presents the question of whether or not there are intrinsic 
differences between these affected and non-affected cells that may stem from underlying 
aRGC heterogeneity. In order to understand which subpopulations of aRGCs are infected 
with ZIKV, the diversity of the aRGCs must first be fully investigated. scRNAseq has 
brought us closer to this necessary breakthrough. Li et al., (2020) used single-cell droplet 
capture to perform a high-throughput gene expression analysis of mouse neocortical wall 
at E15.5. Using Seurat gene expression analysis in R, they found that each NPC class could 
be broken down further into sub-types using differentially expressed genes. This published 
data set serves as an excellent means for investigation into NPC heterogeneity. Differential 
gene expression between hypothesized clusters can be used to design markers to find these 
cell types in vivo. In fact, two different clusters of aRGCs were shown to express genes 
specific to the VZ (Li et al., 2020). Given the differential vulnerability to ZIKV induced 
basal fiber perturbation seen in Chapter 3, we sought to determine whether genes 
differentially expressed between these two groups may identify new tools to study aRGC 
heterogeneity in vivo (Li et al., 2020). 
 To develop markers for these two clusters of aRGCs, differential gene expression 
in Group 1 and Group 2 was compared to each other, against other NPCs, and neuron 
clusters to create a list of markers specific to Group 1 cells or Group 2 cells (Fig. 11). 
Prc1 (Protein Regulator of Cytokinesis 1) and AXL (AXL Receptor Tyrosine Kinase) 
were top candidate genes for Group 1 and MFAP2 (Microfibril Associated Protein 2) and 





(Table 1). Conserved regulatory regions proximal to the transcriptional start site of the 
candidate genes were sub-cloned upstream of the Cre coding sequence in a plasmid 
backbone and then tested with IUE in conjunction with the CAG-StopLight reporter 
plasmid at 24 and 48hrs. This reporter system will produce mCherry+ cells that are 
specific to the Cre-driver and label all other electroporated cells with ZsGreen. Analysis 
of this tissue showed mCherry+ cells in the VZ with the expected morphology and 
location of aRGCs (Fig. 12). Prc1 expression was found in a larger proportion of cells 
compared to MFAP2. Prc1+ cells also showed greater proliferative potential compared to 
MFAP2+ cells as seen in the proportion of red cells counted between 24 and 48 hrs (Fig. 
12I-J).  
 The top 2 candidates for each of the cortical aRGC clusters were also used to design 
oligonucleotide probes for multiplexed in situ hybridization (Table 1). RNAscope was used 
to assess specificity of candidate marker genes in vivo. For Group 1 aRGCs, Prc1 and AXL 
were selected based on the differential gene expression analysis results. For Group 2 
aRGCs, MFAP2 and Robo4 were selected as the top two markers candidates. Prc1 
RNAscope was performed on 24hr MFAP2-Cre CAG-LNL-Lyn-GFP electroporated tissue 
to measure the overlap of the two markers in aRGCs. It was found that only 7% of the 
MFAP2+ electroporated cells were also positive for Prc1 (Fig. 13A-E). This finding 
confirms the scRNAseq results from Li et al., (2020), that 2 separate populations of aRGCs 





 Given the separation of Prc1+ and MFAP2+ populations, we next tested if these 
groups were differentially vulnerable to ZIKV infection by multiplexing RNAscope probes 
against Prc1, MFAP2, and ZIKV. To do this, we followed the standard RNAscope protocol 
on fixed frozen brains. It was found that ZIKV co-labeled Prc1+ cells significantly more 
than MFAP2+ cells. In fact, 63% of Prc1+ cells were infected while 35% of MFAP2+ cells 
were infected at 2DPI (Fig. 14). Using RNAscope probes, the separation of Prc1 and 
MFAP2 expression was found again in vivo. Additionally, by multiplexing our markers for 
Group 1 and Group 2 with a probe for ZIKV, we were able to demonstrate differential 
vulnerability to ZIKV infection between the two aRGC populations.  
AXL as a Group 1 identifier and candidate viral entry receptor 
Interestingly, AXL was found to be a candidate marker for Group 1 aRGCs in our 
analyses of differentially expressed genes that were specific to one of the two aRGC 
groups. Despite evidence that AXL is not necessary but sufficient to cause ZIKV infection, 
we sought to test if the vulnerability to ZIKV was correlated to AXL expression (Wells et 
al., 2016). RNAscope of Prc1 with AXL and MFAP2 with AXL corroborated the scRNAseq 
data and showed that expression levels of AXL are higher in Group 1 Prc1+ cells compared 
to Group 2 MFAP2+ cells (Fig. 15B). However, 26% of MFAP2+ cells did express AXL, 
showing that AXL expression is not exclusive to Group 1 aRGCs (Fig. 15D). When 
multiplexing AXL with ZIKV and the respective group marker, it was found that AXL, Prc1, 
and ZIKV were co-expressed at high levels (Fig. 15F). To assess if all AXL+ cells were 





the population of interest. Ex) (AXL+, ZIKV+)/ZIKV+. Roughly 95% of AXL+ cells were 
infected (Fig. 16) and conversely, 96% of ZIKV+ cells express AXL (Fig. 16). The 
correlation between AXL expression and ZIKV infection is consistent with previous 
findings in vitro (Miner et al., 2016, Meertans et al., 2012, Onorati et al., 2016). This 
method can be used to test other viral entry candidates in the future.  
Lineage preferences of aRGC subtypes 
 The balance of direct and indirect neurogenesis leads to the precise layering of a 
wide variety of neurons with various functions throughout the cortex. The current study 
suggests that there are two distinct populations of aRGCs. The purpose of two classes of 
aRGCs with distinct transcriptional profiles is not yet known. For example, it is unclear if 
specific groups of aRGCs differ in their primary mode of division and whether aRGCs are 
primed for direct vs indirect neurogenesis. To test this, we fate mapped Prc1+ cells with 
Prc1-Cre and CAG-LNL-LYN-GFP or MFAP2+ cells with MFAP2-Cre and CAG-LNL-
LYN-GFP. IHC was then used to stain the electroporated tissue with Tbr2 (bIPCs) and 
Tuj1 (immature neurons). Analysis of percent co-labeled cells showed that the Group 1 
Prc1+ lineage cells were predisposed to direct neurogenesis fate at 24 and 48hrs after 
electroporation (Fig. 17A-C). Group 2 MFAP2+ lineage cells produced more Tbr2+ cells at 
24 and 48hrs after electroporation (Fig. 17D-F). While Prc1+ cells gave rise to neurons 
preferentially and MFAP2+ cells produced disproportionately high numbers of progenitors, 
it should be noted that in both cases, the majority of electroporated cells were negative for 





expected from the aRGC class (Fig. 17). These experiments therefore not only present an 
in vivo validation of the scRNAseq data that suggested two cortical aRGC classes, but the 
results also show significant functional differences between these groups of aRGCs. 
Specifically, we have shown evidence that Group 1 and Group 2 aRGCs are two distinct 
groups of cells in vivo which have differential vulnerability to ZIKV and give rise to 
separate neurogenic streams. 
Discussion 
 Heterogeneity of NPCs has been a topic of investigation for decades because of 
their role in corticogenesis. New advances in scRNAseq and multiplexed ISH have finally 
allowed for rigorous investigation into the heterogeneity of NPCs and their progeny. 
However, scRNAseq results without validation in vivo, need to be taken with a grain of 
salt. This is because the analysis of scRNAseq data in Seurat allows for any number of 
clusters to be entered, making the number of “cell types” somewhat arbitrary. There are 
statistical guidelines in place to try to choose the most accurate number of clusters possible, 
but these clusters still need to be validated in vivo before accepting the existence of a new 
NPC class. 
 The two methods used in this work to test markers from scRNAseq data were IUE 
and RNAscope. Subcloning the promotor sequence into a Cre vector to use in conjunction 
with a CAG-StopLight reporter allows for the visualization of the morphology and location 
of the promotor specific cells versus the non-specific electroporated cells. Cre-
recombination does, however, limit the temporal range of cells labeled. Prc1 and MFAP2 





potential of cell labeling in these aRGC groups. RNAscope, on the other hand, labels all 
the cells expressing those mRNAs in the tissue but lack the full cell morphology that is 
elucidated with IUE. Additionally, RNAscope is limited in that it shows transcripts which 
may not be translated. This may serve as an important aspect of analysis given that Li et 
al., (2020) found that aRGCs may express Tbr2 transcript but not protein, seeming to prime 
those aRGCs towards production of Tbr2+ bIPCs. Together, these methods are 
complimentary and amenable to IHC in order to thoroughly study cell type heterogeneity 
in the brain.  
 RNAscope allows us to probe the expression of our Group 1 and 2 markers, finding 
separate transcriptional profiles between the two groups including increased AXL 
expression in Group 1 aRGCs. This finding adds another correlation between AXL 
expression and ZIKV infection (Nowakowski et al., 2016). However, experimental 
evidence from Wells et al., (2016) discredit the role of AXL in ZIKV infection. This 
discrepancy may be due to the differences in AXL function between humans and mice. It 
may also be the case that there are mediating variables that are responsible for increased 
infection. For instance, AXL has high expression levels in rapidly proliferating cell types. 
Perhaps mitotic cells are at greater risk for infection and these cells merely happen to 
express high amounts of AXL, as it plays a role in the regulation of proliferation (Ammoun 
et al., 2016). 
 Preliminary staining of Tuj1 and Tbr2 in brains electroporated with either Prc1-Cre 
or MFAP2-Cre and CAG-LNL-Lyn-GFP indicate preferential lineage fate of Group 1 





preferentially infected by ZIKV. In agreement, Li et al. (2020) showed transcriptional 
priming and pseudotiming evidence that aRGC Group 1 (Prc1+) may be fated towards 
direct neurogenesis while aRGC Group 2 (MFAP2+) cells are primed towards the Tbr2+ 
bIPC lineage. Similarly, Fabra-Beser et al. recently described aRGC heterogeneity based 
on Sox9 expression, which is also differentially expressed between aRGC groups 1 and 2 
in our data (Log fold change: -0.62, Adjusted p-value: 0.00022). Ugomma et al., 2020 
aimed to characterize the molecular signatures of cellular subtypes that may exist at the 
earliest stages of neurogenesis by performing scRNAseq across regions of the developing 
human brain. They found that progenitors express region-specific transcription factors 
depending on their location in the brain. In the telencephalon, they identified more 
numerous progenitor populations than had previously been described. These works support 
the hypothesis that delineation in neurogenic streams contributes to the heterogeneity of 
excitatory neurons in the cerebral cortex. Their work, in combination with the data 
described here, promotes the strategy of using markers to follow the progression from 
aRGCs to adult neurons to better understand how pre-natal ZIKV infection will impact 
adult circuits in the brain. Future studies should use the tools developed here to perform 
live imaging with Prc1 and MFAP2 electroporated tissue to further assess lineage 
differences in their progeny. Knocking out Prc1 and MFAP2 would provide additional 
information as so how each of these groups contribute to neuronal diversity in each layer 
of the cerebral cortex. Not only will this improve our understanding of cortical 
development but may also have important implications in neuronal diversity of patients 






















Group Fold change P-value 
Group1-Prc1 6.3 5.6E-35 
Group1-Axl 2.3 9.87E-3 
Group2-MFAP2  0.64  1.54E-08 
Group2-Robo4 6.2 1.3E-32 
 
Figure 11. Published t-SNE of E15.5 mouse cortex. The neocortical wall of E15.5 
mouse brain were dissected for dissociation in ddSeq. Colors represent cell types based 
on their gene expression. The bottom right corner shows RGC1 in brown  (318 cells) 
and RGC2 in salmon (381 cells). See Li et al., (2020) for details. 
 
Table 1. Group 1 and 2 aRGC markers chosen from scRNAseq data. The fold 
change represents differential expression between Group 1 aRGCs and Group 2 











Figure 12. Fate mapping of aRGC types. E14.5 mice were electroporated with Prc1-
Cre or MFAP2-Cre and CAG-StopLight and collected 24 or 48hrs later. A) IUE with 
Prc1-Cre and CAG-StopLight produced VZ-localized mCherry+ cells. A composite 
image from Prc1-Cre experiments with non-specific electroporated cells in green (B) 
and (C) Prc1+ cells in red. Scale bar: 50µm. Red and green cell number were counted 
and normalized to the total number of electroporated cells for (D) 24hr and (E) 48hr 
time points. F) IUE with MFAP2-Cre and CAG-StopLight produced VZ localized 
mCherry+ cells. A composite image from MFAP2-Cre and CAG-SL recombination 
allowing visualization of electroporated cells in green (G) and (H) MFAP2+ cells in red. 
Scale bar: 50µm. Red and green cell number were counted and normalized to the total 
number of electroporated cells for 24hr (I) and 48hr (J) time points. (n = 4 per 
condition). Statistical significance was calculated using unpaired t test (* indicates 












Figure 13. MFAP2 and Prc1 label different aRGC populations. A) E13.5 mice were 
electroporated with MFAP2-Cre and CAG-LNL-LYN-GFP and collected 48hrs later. 
Prc1+ cells were labeled with RNAscope (red), electroporated MFAP2+ cells with GFP 
and nuclei were labeled with Hoechst (blue). Scale bar: 15µm. B) Prc1 RNAscope 
alone. C) 20x magnification image with no zoom shows marker labeling in the VZ and 
SVZ 48hrs after electroporation. Scale bar: 100µm. D) Zoom of a Prc1+ cell in red 
neighboring a MFAP2+ in green. Scale bar: 10µm. E) Cells counted positive for 
RNAscope by including 2 or more puncta within the cell body that were co-localized 
with GFP from electroporation were normalized to the total number of electroporated 
cells in the field to determine percent co-localized cell number. Seven percent of the 
electroporated cells were positive for Prc1 RNAscope (n=4). Statistical significance 
was calculated using unpaired t test (* indicates p<0.05) and error bars represent 
standard error. F) E15.5 cryosectioned tissue was stained for MFAP2 (green), and Prc1 
(red) using RNAscope. Scale bar: 50µm. G) Prc1+ cells, MFAP2+ cells, and co-labeled 
cells were counted in 20-micron z-stack images (n = 4). Statistical significance was 










Figure 14. MFAP2+ aRGCs show lower infection rates compared to Prc1+ 
aRGCs. A) Multiplexed RNAscope staining shows fewer infected MFAP2+ cells 
compared to Prc1+ cells. E15.5 2DPI infected tissue was stained for ZIKV (green), 
Prc1 (red), and MFAP2 (white) using RNAscope. Scale bar: 50µm. B) Prc1+ cells 
are more vulnerable to ZIKV infection than MFAP2+ cells. Statistical significance 
was calculated using unpaired t test (* indicates p<0.05) and error bars represent 














Figure 15. Prc1+ cells express the candidate ZIKV entry receptor AXL. A) Prc1 
and AXL are highly expressed in the telencephalic germinal zone. E15.5 tissue 
was stained for AXL (red) and Prc1 (white) using RNAscope. Scale bar: 80µm. B) 
Over 90% of Prc1+ cells co-express AXL. (n = 4). Statistical significance was 
calculated using unpaired t test (* indicates p<0.05) and error bars represent 
standard error. C) The majority of MFAP2+ cells are negative for AXL 
expression. The white box outlines a zoomed example of MFAP2+ cells with and 
without AXL co-expression showing variability of AXL expression in MFAP2+ cells. 
Scale bar: 10µm. D) AXL expression is decreased in MFAP2+ cells compared to 
Prc1+ cells. Despite the lower infection rate in Group 2 aRGCs, 26.5% of MFAP2+ 
cells co-expressed AXL. E) ZIKV infection correlates with AXL expression in 
Prc1+ cells. E15.5 tissue was stained for Prc1 (red) and AXL (white) and ZIKV 
(green) using RNAscope. Scale bar: 10µm. F) The majority of Prc1+, ZIKV+ cells 
also express AXL. Over 95% of infected Prc1+ cells were co-labeled with AXL 
RNAscope. Statistical significance was calculated using unpaired t test (* indicates 









Figure 16. AXL and ZIKV were found to be colocalized in the same cells. 
E15.5 2dpi infected tissue was stained for ZIKV and AXL using RNAscope. 
The number of AXL+ and ZIKV+ cells/ AXL+= 95% (SE=2.8 n = 4). The 
number of AXL+ and ZIKV+ cells/ ZIKV+= 96% (SE=0.7 n=4). Statistical 
significance was calculated using unpaired t test (* indicates p<0.05) and error 







Figure 17. Group 1 and 2 aRGCs give rise to direct and indirect neurogenic 
lineages of daughter cells, respectively. A) Fate mapped Prc1+ cells are co-
localized with immature neuron marker Tuj1. E13.5 mice were electroporated 
with Prc1-Cre and CAG-LNL-LYN-GFP and collected 24hrs or 48hrs later and 
stained for Hoechst (blue), Tuj1 (red), and Tbr2 (white). Scale bar: 10µm. A white 
box outlines a zoomed example of co-labeled cells at 24hrs. B) Immunostained GFP 
labeled Prc1+ cells were predominantly Tuj1+ (75%) at 24 hrs (n = 4). Tbr2 co-
localized SE=0.0.4% and Tuj1 co-localized SE=2.9%. C) At 48hrs, the majority of 
Prc1+ cells remained Tuj1+ (n=4). Tbr2 co-localized SE=0.4% and Tuj1 co-
localized SE=0.31%. Statistical significance was calculated using unpaired t test (* 
indicates p<0.05) and error bars represent standard error. D) Fate mapped MFAP2+ 
cells are co-labeled with Tbr2. E13.5 mice were electroporated with MFAP2-Cre 
and CAG-LNL-LYN-GFP. They were collected 24hrs or 48hrs later and stained for 
Hoechst (blue), Tuj1 (red), and Tbr2 (white). A white box outlines a zoomed 
example of co-labeled cells. E) Immunostained GFP labeled MFAP2+ cells were 
predominantly Tbr2+ (83%) at 24 hrs (n = 4). Tbr2+ co-localized SE=0.4% and 
Tuj1+ co-localized SE=0.31%. F) At 48hrs, the majority of MFAP2+ cells were still 
Tbr2+ but with a greater increase in Tuj1+ immature neuron production as expected 
(n = 4). Tbr2+ co-localized SE=0.40% and Tuj1+ co-localized SE=0.41%. Statistical 
significance was calculated using unpaired t test (* indicates p<0.05) and error bars 







Development of an in vivo mouse model of ZIKV infection and microencephaly 
This work provides a thorough and in-depth explanation of ZIKV infection by 
timepoint and cell type. It quantifies, for the first time, the detrimental phenotype of ZIKV 
induced loss of the aRGC basal processes. Additionally, this work suggests that there are 
multiple groups of aRGCs with functional differences including vulnerability to ZIKV and 
lineage fate. The model and markers used here lay the groundwork for important future 
work regarding ZIKV infections in the brain as well as corticogenesis in the typically 
developing brain. The work presented here demonstrates how the live, active form of ZIKV 
can be added to cell type specific IUE protocols to produce an effective model of viral 
infection in vivo without the need for interferon knock-out or inactivation of virus. This 
methodological development was much needed in the field of Zika research as previous 
research utilized less biologically relevant versions or titers of ZIKV, used virus that was 
not replication-competent, or were conducted using a model that did not encompass 
essential aspects of neural development and cell type specificity. Compared to previous 
studies that used higher concentrations of virus than would be delivered from a mosquito 
to a host, the concentration and strain of virus used here is most appropriate to study fetal 
infection in the Americas (Dudley et al., 2017). Additionally, by administering an 
appropriate concentration of ZIKV directly into developing mice, we were able to 
comprehensively study multiple interacting components of brain development across time 





Additionally, this model made possible, for the first time, the ability to study the 
time course of ZIKV infection in a developing brain. With this assessment of infection 
across time we were able to investigate whether the age at which infection occurs affects 
the severity of outcome as well as which specific NPC types are targeted throughout the 
various stages of development. It was found that aRGCs are infected preferentially at 1-
3DPI while bIPCs became preferentially infected at 4DPI. This thorough time course study 
may explain why some studies have found aRGCs to be the primary target while others 
have found IPCs to be ZIKV’s primary target. This model presents the longest time course 
of pre-natal ZIKV infection which is necessary to understand both the progression of 
infection across time but also the limitations of the model. It was discovered that the pre-
natal mouse immune response was not developed enough to mount a sufficient attack 
against ZIKV to prevent infection even at later time points in neurogenesis. This is an 
important difference between human development and the mouse model described here. 
This work addresses many existing issues in the Zika research field by providing a new 
method for infection that allows for the longitudinal study of how ZIKV preferentially 
targets neural progenitor cells during development, contributing to microencephaly. 
 Additionally, this model of infection will prove useful for the study of other live 
viruses. With the advancing COVID-19 pandemic, research regarding how this virus 
infects and impacts the brain is critical. Recent findings using MRI from patients with 
COVID-19 show structural changes due to infection (Akiko Iwasaki et al., 2020) and 
COVID-19 infected brain organoids show significant decreases in number of synapses after 





recombination creates a model system to answer questions about how COVID-19 affects 
the brain in vivo. 
By using cell-type specific promoters and fate mapping strategies, in combination 
with ZIKV infection, we were able to parse apart the differential effects of ZIKV on 
individual classes of NPCs across developmental periods. Our model of ZIKV infection 
produced a microencephaly phenotype that could be studied at different developmental 
stages and after infection at different time points. Our studies suggest that the etiology of 
this microcephaly phenotype is a combination of cell death, loss of proliferation, and 
decreased numbers of aRGC basal fibers required for neuronal migration.  
 Given the importance of aRGCs in neural development and their limited 
survivability and proliferation in the presence of ZIKV, we sought to further understand 
the effects of ZIKV on the aRGC population. Whole-cell labeling revealed that 60% of 
aRGC basal fibers were disrupted after 2dpi. These findings were confirmed using DiI 
labeling at the same time point. Basal processes are the structural fibers that neurons use 
for migration to the superficial layers of the cortex. Without this essential cytoarchitecture, 
neurons fail to migrate and are cleared from the system, leading to decreased cortical 
thickness. As aRGCs basal fibers are required for neural migration and maturation, 
disturbances in this scaffolding could further contribute to the microencephaly phenotypes 
and present a mechanism for the previously described decreased in neuronal migration in 






Heterogeneity of aRGCs and differential vulnerability to ZIKV 
 Using published scRNAseq data, we identified markers specific to two sub-groups 
of aRGCs and developed tools to validate their existence in vivo. IUE and RNAscope 
experiments showed small amounts of overlap in their expression as expected from the 
scRNAseq data. Additionally, Group 1 and 2 aRGCs were found to be differentially 
vulnerable to ZIKV and may give rise to functionally separate daughter cells. 
One possible mechanism responsible for the differential vulnerability to ZIKV 
infection between Group 1 Prc1+ cells and Group 2 MFAP2+ cells is the increased 
expression of AXL in the Group 1 Prc1+ cells. Previous findings suggest that AXL is 
involved in the viral entry of ZIKV suggesting that the greater expression of AXL in Group 
1 could explain the increased ZIKV infection in this sub-class of aRGCs. However, our 
findings also suggest that AXL is not necessary for infection as 4% of ZIKV+ cells were 
AXL- (Fig. 16). Our data presented here corroborate the findings of Nowokowski et al. 
(2016) who showed that AXL is highly expressed in aRGCs and functions as a viral entry 
receptor while also supporting the results of Wells et al. (2016) which showed cells can 
become infected without the presence of AXL. One AXL-independent means of viral 
infection could be due to the process of cell division that generates infected cells. Our 
results show that aRGCs are more highly infected at 1-3dpi and bIPCs are more heavily 
infected at 3dpi. aRGCs divide to self-renew and give rise to bIPCs therefore, if an already 
infected aRGC, with a low-grade infection is able to successfully divide, it could generate 
a bIPC that already has virions present in the cytoplasm at the time of mitosis. This work 
shows that AXL can be used as a cell type specific marker for Group 1 aRGCs and is highly 
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correlated with ZIKV infection. Knowledge of the cell types vulnerable to ZIKV allow for 
future work to determine ZIKV-host interactions. Our work suggests that AXL may mediate 
viral entry given the high correlation of AXL expression to infected cells. Additional 
experiments are required to test this hypothesis and to determine if other receptors play a 
role in ZIKV endocytosis. Only then can effective inhibitors of ZIKV envelope protein be 
developed to stop infection before brain malformations occur. 
The research presented here not only expands on our understanding of how ZIKV 
infection impacts neural development, but also identifies a novel sub-type of aRGCs, which 
previously were believed to be a largely homogenous population. This work supports the 
findings of Li et al., 2020, Heaver et al., 2020, and Ugomma et al., 2020 that all suggest a 
shift away from the previous dogma that aRGCs are a homogenous group of neural stem 




Reagent type or resource Designation Source or reference Identifiers Additional information
Sequence-based reagent Prc1 ISH probe Advanced Cell Diagnostics 57712 MFISH
Sequence-based reagent AXL ISH probe Advanced Cell Diagnostics 450931 MFISH
Sequence-based reagent MFAP2 ISH probe Advanced Cell Diagnostics 445421 MFISH
Sequence-based reagent Robo4 ISH probe Advanced Cell Diagnostics 466321 MFISH
Sequence-based reagent V-ZIKA-06 ISH probe Advanced Cell Diagnostics 521511 MFISH
Antibody Ns2b Genetex GTX133308 anti-rabbit (1 250)
Antibody CC3 Cell Signaling 9661-s anti-rabbit(1 250)
Antibody Ki67 BS Pharmigen MAB1567 anti-mouse (1 250)
Antibody Ph3 Millipore 06-570 anti-rabbit (1 300)
Antibody Tbr2 Millipore, Santa Cruz AB2283, sc-293481 anti-rabbit (1 300), anti-mouse (1 250)
Antibody Sox2 Santa Cruz sc-17320 anti-goat (1 250)
Antibody Tuj1 Santa Cruz sc-80005 anti-mouse (1 250)
Secondary goat anti-rabbit Invitrogen A11008 goat anti rabbit (1 500
Secondary goat anti-mouse Invitrogen A21050 goat anti mouse (1 500)
Secondary donkey anti-mouse Invitrogen A2202 donkey anti mouse (1 500)
Secondary donkey anti-rabbit Invitrogen A31573 donkey anti rabbit (1 500)
Vector Tbr2 Cre Tyler WA et al.  Neural Precursor Lineages Specify Distinct Neocortical Pyramidal Neuro  IUE
Vector Prc1 Cre available upon request IUE
Vector MFAP2 Cre available upon request IUE
Vector CAG-StopLight Montana Molecular IUE
Vector CAG-LNL-LYN-GFP available upon request IUE
Software, algorithm R https //www.r- project.org SCR_001905
Software  algorithm Seurat https //satijalab. org/seurat/ RRID SCR 007322
Software, algorithm Fiji https //imagej.ne t/Fiji RRID SCR_002285
Software  algorithm Prism https //www.gra phpad.com/scie ntific- software/prism/ RRID SCR 002798
Software, algorithm Sigma Plot https //systatsoftware.com/downloads/download-sigmaplot/
Primers Prc1 forward TACCGTTCTCCGTCCCGCTCGAGGGGCAGAGCCG
Primers Prc1 reverse GCTCTGCCCCTCGAGCGGGACGGAGAACGG
Primers Prc1 forward GGCGAATTGGGTACCCTTGGCTTGCTAGGGTGTGA
Primers Prc1 reverse CCCTAGCAAGCCAAGCGCTATC
Primers Robo4 forward GGCGAATTGGGTACCCATGCATTTGGAGTTTCCATGTCCT 
Primers Robo4 reverse GCTCTGCCCCTCGAGGGCTGCTCTCGGCTCC
Primers MFAP2 forward GGCGAATTGGGTACCACTCGATCTCCCTTAATCTGCCT
Primers MFAP2 reverse GGCGAATTGGGTACCACTCGATCTCCCTTAATCTGCCT
Primers ZIKV forward AARTACACATACCARAACAAAGTGGT
Primers ZIKV reverse TCCRCTCCCYCTYTGGTCTTG
Table 2. Key Resource Table 
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